Sars-cov2 anche bambine e bambini sani si ammalano

Array ( [body] => Array ( [#theme] => field [#weight] => 0 [#title] => Body [#access] => 1 [#label_display] => hidden [#view_mode] => teaser [#language] => und [#field_name] => body [#field_type] => text_with_summary [#field_translatable] => 0 [#entity_type] => node [#bundle] => box_lancio_news [#object] => stdClass Object ( [vid] => 348017 [uid] => 2032 [title] => Sars-cov2 anche bambine e bambini sani si ammalano [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 75933 [type] => box_lancio_news [language] => it [created] => 1614860731 [changed] => 1614860747 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1614860747 [revision_uid] => 2032 [body] => Array ( [und] => Array ( [0] => Array ( [value] =>

A dimostrare che l’infezione da Sars-Cov2 può presentarsi in modo serio e con complicanze importanti anche nelle bambine e nei bambini piccoli che non presentano patologie preesistenti è uno studio coordinato dal professore Giovanni Di Salvo del Dipartimento di Salute della donna e del Bambino dell’Università di Padova (con Elena Reffo e Valentina Stritoni). Inflammatory syndrome in children associated with COVID-19 complicated by acute myocardial infarction, questo il titolo della ricerca, è stato pubblicato sull’«European Heart Journal», la più autorevole rivista cardiologica al mondo ed è considerato un unicum al mondo nella letteratura della cardiologia pediatrica, per come è stato trattato e per il buon esito del trattamento.

Lo studio ha preso in esame la storia medica di un bambino di 4 anni, precedentemente sano, ricoverato per febbre, congiuntivite e rush cutaneo presso l’ospedale di riferimento territoriale della propria residenza. Il tampone nasofaringeo risulta negativo, mentre gli anticorpi IgG anti SARS-Cov2 sono positivi. Infatti, circa un mese prima un suo familiare aveva contratto il Covid-19, mentre il bimbo era sempre stato asintomatico; aveva evidentemente contratto il Covid anche lui senza accorgersene, come accade spesso nei bambini, fatto che spiegherebbe la negatività al tampone. Una volta ricoverato, le condizioni si aggravano e viene per questo trasferito presso la cardiologia pediatrica dell’Azienda Ospedale/Università di Padova

Qui viene fatta diagnosi di dilatazione aneurismatica della coronaria sinistra con occlusione trombotica determinante un infarto acuto del miocardio. «Il piccolo viene trattato con successo, la notte di Natale, in terapia intensiva pediatrica, per questa grave e potenzialmente letale complicanza, con un protocollo modificato di trombolisi, utilizzato per la prima volta al mondo dai cardiologi pediatri di Padova in un bambino affetto da sindrome infiammatoria secondaria al Covid – spiega il Di Salvo. Abbiamo utilizzato un farmaco che scioglie i coaguli nel sangue, utilizzando così un protocollo mai applicato prima nei bambini affetti da Covid-19, ma usato nei pazienti pediatrici affetti dalla malattia di Kawasaki, caratterizzata da complicanze vascolari che possono interessare le arterie coronariche nei bambini.»

[summary] => [format] => 2 [safe_value] =>

A dimostrare che l’infezione da Sars-Cov2 può presentarsi in modo serio e con complicanze importanti anche nelle bambine e nei bambini piccoli che non presentano patologie preesistenti è uno studio coordinato dal professore Giovanni Di Salvo del Dipartimento di Salute della donna e del Bambino dell’Università di Padova (con Elena Reffo e Valentina Stritoni). Inflammatory syndrome in children associated with COVID-19 complicated by acute myocardial infarction, questo il titolo della ricerca, è stato pubblicato sull’«European Heart Journal», la più autorevole rivista cardiologica al mondo ed è considerato un unicum al mondo nella letteratura della cardiologia pediatrica, per come è stato trattato e per il buon esito del trattamento.

Lo studio ha preso in esame la storia medica di un bambino di 4 anni, precedentemente sano, ricoverato per febbre, congiuntivite e rush cutaneo presso l’ospedale di riferimento territoriale della propria residenza. Il tampone nasofaringeo risulta negativo, mentre gli anticorpi IgG anti SARS-Cov2 sono positivi. Infatti, circa un mese prima un suo familiare aveva contratto il Covid-19, mentre il bimbo era sempre stato asintomatico; aveva evidentemente contratto il Covid anche lui senza accorgersene, come accade spesso nei bambini, fatto che spiegherebbe la negatività al tampone. Una volta ricoverato, le condizioni si aggravano e viene per questo trasferito presso la cardiologia pediatrica dell’Azienda Ospedale/Università di Padova

Qui viene fatta diagnosi di dilatazione aneurismatica della coronaria sinistra con occlusione trombotica determinante un infarto acuto del miocardio. «Il piccolo viene trattato con successo, la notte di Natale, in terapia intensiva pediatrica, per questa grave e potenzialmente letale complicanza, con un protocollo modificato di trombolisi, utilizzato per la prima volta al mondo dai cardiologi pediatri di Padova in un bambino affetto da sindrome infiammatoria secondaria al Covid – spiega il Di Salvo. Abbiamo utilizzato un farmaco che scioglie i coaguli nel sangue, utilizzando così un protocollo mai applicato prima nei bambini affetti da Covid-19, ma usato nei pazienti pediatrici affetti dalla malattia di Kawasaki, caratterizzata da complicanze vascolari che possono interessare le arterie coronariche nei bambini.»

[safe_summary] => ) ) ) [field_date_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [value] => 2021-03-04T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_etichetta_box_lancio_news] => Array ( ) [field_img_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [fid] => 90886 [uid] => 2032 [filename] => shutterstock_133068686.jpg [uri] => public://shutterstock_133068686.jpg [filemime] => image/jpeg [filesize] => 56206 [status] => 1 [timestamp] => 1614860731 [type] => image [field_file_image_alt_text] => Array ( ) [field_file_image_title_text] => Array ( ) [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( [height] => 630 [width] => 1200 ) [height] => 630 [width] => 1200 [alt] => bambino [title] => ) ) ) [field_link_alla_news] => Array ( ) [field_link_esterno_news] => Array ( ) [field_pagina_associata] => Array ( ) [field_link_etichetta] => Array ( ) [field_abstract_news] => Array ( [und] => Array ( [0] => Array ( [value] => Uno studio padovano unico nel mondo, dimostra come l’infezione da Sars-Cov2 può presentarsi in modo serio e con complicanze importanti anche nelle bambine e nei bambini piccoli che non presentano patologie preesistenti [format] => [safe_value] => Uno studio padovano unico nel mondo, dimostra come l’infezione da Sars-Cov2 può presentarsi in modo serio e con complicanze importanti anche nelle bambine e nei bambini piccoli che non presentano patologie preesistenti ) ) ) [field_allegato_news] => Array ( ) [field_categorie_news] => Array ( [und] => Array ( [0] => Array ( [tid] => 2264 ) ) ) [field_pub_date] => Array ( [und] => Array ( [0] => Array ( [value] => 2021-03-04T00:00:00 [value2] => 2021-08-04T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_layout_news] => Array ( [und] => Array ( [0] => Array ( [value] => single ) ) ) [field_testo_opzionale_news] => Array ( ) [field_url_en_page] => Array ( ) [field_url_en_page_label] => Array ( ) [path] => Array ( [pathauto] => 1 ) [name] => francesca.forzan [picture] => 0 [data] => b:0; [num_revisions] => 2 [current_revision_id] => 348017 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [value] =>

A dimostrare che l’infezione da Sars-Cov2 può presentarsi in modo serio e con complicanze importanti anche nelle bambine e nei bambini piccoli che non presentano patologie preesistenti è uno studio coordinato dal professore Giovanni Di Salvo del Dipartimento di Salute della donna e del Bambino dell’Università di Padova (con Elena Reffo e Valentina Stritoni). Inflammatory syndrome in children associated with COVID-19 complicated by acute myocardial infarction, questo il titolo della ricerca, è stato pubblicato sull’«European Heart Journal», la più autorevole rivista cardiologica al mondo ed è considerato un unicum al mondo nella letteratura della cardiologia pediatrica, per come è stato trattato e per il buon esito del trattamento.

Lo studio ha preso in esame la storia medica di un bambino di 4 anni, precedentemente sano, ricoverato per febbre, congiuntivite e rush cutaneo presso l’ospedale di riferimento territoriale della propria residenza. Il tampone nasofaringeo risulta negativo, mentre gli anticorpi IgG anti SARS-Cov2 sono positivi. Infatti, circa un mese prima un suo familiare aveva contratto il Covid-19, mentre il bimbo era sempre stato asintomatico; aveva evidentemente contratto il Covid anche lui senza accorgersene, come accade spesso nei bambini, fatto che spiegherebbe la negatività al tampone. Una volta ricoverato, le condizioni si aggravano e viene per questo trasferito presso la cardiologia pediatrica dell’Azienda Ospedale/Università di Padova

Qui viene fatta diagnosi di dilatazione aneurismatica della coronaria sinistra con occlusione trombotica determinante un infarto acuto del miocardio. «Il piccolo viene trattato con successo, la notte di Natale, in terapia intensiva pediatrica, per questa grave e potenzialmente letale complicanza, con un protocollo modificato di trombolisi, utilizzato per la prima volta al mondo dai cardiologi pediatri di Padova in un bambino affetto da sindrome infiammatoria secondaria al Covid – spiega il Di Salvo. Abbiamo utilizzato un farmaco che scioglie i coaguli nel sangue, utilizzando così un protocollo mai applicato prima nei bambini affetti da Covid-19, ma usato nei pazienti pediatrici affetti dalla malattia di Kawasaki, caratterizzata da complicanze vascolari che possono interessare le arterie coronariche nei bambini.»

[summary] => [format] => 2 [safe_value] =>

A dimostrare che l’infezione da Sars-Cov2 può presentarsi in modo serio e con complicanze importanti anche nelle bambine e nei bambini piccoli che non presentano patologie preesistenti è uno studio coordinato dal professore Giovanni Di Salvo del Dipartimento di Salute della donna e del Bambino dell’Università di Padova (con Elena Reffo e Valentina Stritoni). Inflammatory syndrome in children associated with COVID-19 complicated by acute myocardial infarction, questo il titolo della ricerca, è stato pubblicato sull’«European Heart Journal», la più autorevole rivista cardiologica al mondo ed è considerato un unicum al mondo nella letteratura della cardiologia pediatrica, per come è stato trattato e per il buon esito del trattamento.

Lo studio ha preso in esame la storia medica di un bambino di 4 anni, precedentemente sano, ricoverato per febbre, congiuntivite e rush cutaneo presso l’ospedale di riferimento territoriale della propria residenza. Il tampone nasofaringeo risulta negativo, mentre gli anticorpi IgG anti SARS-Cov2 sono positivi. Infatti, circa un mese prima un suo familiare aveva contratto il Covid-19, mentre il bimbo era sempre stato asintomatico; aveva evidentemente contratto il Covid anche lui senza accorgersene, come accade spesso nei bambini, fatto che spiegherebbe la negatività al tampone. Una volta ricoverato, le condizioni si aggravano e viene per questo trasferito presso la cardiologia pediatrica dell’Azienda Ospedale/Università di Padova

Qui viene fatta diagnosi di dilatazione aneurismatica della coronaria sinistra con occlusione trombotica determinante un infarto acuto del miocardio. «Il piccolo viene trattato con successo, la notte di Natale, in terapia intensiva pediatrica, per questa grave e potenzialmente letale complicanza, con un protocollo modificato di trombolisi, utilizzato per la prima volta al mondo dai cardiologi pediatri di Padova in un bambino affetto da sindrome infiammatoria secondaria al Covid – spiega il Di Salvo. Abbiamo utilizzato un farmaco che scioglie i coaguli nel sangue, utilizzando così un protocollo mai applicato prima nei bambini affetti da Covid-19, ma usato nei pazienti pediatrici affetti dalla malattia di Kawasaki, caratterizzata da complicanze vascolari che possono interessare le arterie coronariche nei bambini.»

[safe_summary] => ) ) [#formatter] => text_summary_or_trimmed [0] => Array ( [#markup] =>

A dimostrare che l’infezione da Sars-Cov2 può presentarsi in modo serio e con complicanze importanti anche nelle bambine e nei bambini piccoli che non presentano patologie preesistenti è uno studio coordinato dal professore Giovanni Di Salvo del Dipartimento di Salute della donna e del Bambino dell’Università di Padova (con Elena Reffo e Valentina Stritoni).

) ) [field_img_box_lancio_news] => Array ( [#theme] => field [#weight] => 0 [#title] => Immagine [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_img_box_lancio_news [#field_type] => image [#field_translatable] => 0 [#entity_type] => node [#bundle] => box_lancio_news [#object] => stdClass Object ( [vid] => 348017 [uid] => 2032 [title] => Sars-cov2 anche bambine e bambini sani si ammalano [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 75933 [type] => box_lancio_news [language] => it [created] => 1614860731 [changed] => 1614860747 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1614860747 [revision_uid] => 2032 [body] => Array ( [und] => Array ( [0] => Array ( [value] =>

A dimostrare che l’infezione da Sars-Cov2 può presentarsi in modo serio e con complicanze importanti anche nelle bambine e nei bambini piccoli che non presentano patologie preesistenti è uno studio coordinato dal professore Giovanni Di Salvo del Dipartimento di Salute della donna e del Bambino dell’Università di Padova (con Elena Reffo e Valentina Stritoni). Inflammatory syndrome in children associated with COVID-19 complicated by acute myocardial infarction, questo il titolo della ricerca, è stato pubblicato sull’«European Heart Journal», la più autorevole rivista cardiologica al mondo ed è considerato un unicum al mondo nella letteratura della cardiologia pediatrica, per come è stato trattato e per il buon esito del trattamento.

Lo studio ha preso in esame la storia medica di un bambino di 4 anni, precedentemente sano, ricoverato per febbre, congiuntivite e rush cutaneo presso l’ospedale di riferimento territoriale della propria residenza. Il tampone nasofaringeo risulta negativo, mentre gli anticorpi IgG anti SARS-Cov2 sono positivi. Infatti, circa un mese prima un suo familiare aveva contratto il Covid-19, mentre il bimbo era sempre stato asintomatico; aveva evidentemente contratto il Covid anche lui senza accorgersene, come accade spesso nei bambini, fatto che spiegherebbe la negatività al tampone. Una volta ricoverato, le condizioni si aggravano e viene per questo trasferito presso la cardiologia pediatrica dell’Azienda Ospedale/Università di Padova

Qui viene fatta diagnosi di dilatazione aneurismatica della coronaria sinistra con occlusione trombotica determinante un infarto acuto del miocardio. «Il piccolo viene trattato con successo, la notte di Natale, in terapia intensiva pediatrica, per questa grave e potenzialmente letale complicanza, con un protocollo modificato di trombolisi, utilizzato per la prima volta al mondo dai cardiologi pediatri di Padova in un bambino affetto da sindrome infiammatoria secondaria al Covid – spiega il Di Salvo. Abbiamo utilizzato un farmaco che scioglie i coaguli nel sangue, utilizzando così un protocollo mai applicato prima nei bambini affetti da Covid-19, ma usato nei pazienti pediatrici affetti dalla malattia di Kawasaki, caratterizzata da complicanze vascolari che possono interessare le arterie coronariche nei bambini.»

[summary] => [format] => 2 [safe_value] =>

A dimostrare che l’infezione da Sars-Cov2 può presentarsi in modo serio e con complicanze importanti anche nelle bambine e nei bambini piccoli che non presentano patologie preesistenti è uno studio coordinato dal professore Giovanni Di Salvo del Dipartimento di Salute della donna e del Bambino dell’Università di Padova (con Elena Reffo e Valentina Stritoni). Inflammatory syndrome in children associated with COVID-19 complicated by acute myocardial infarction, questo il titolo della ricerca, è stato pubblicato sull’«European Heart Journal», la più autorevole rivista cardiologica al mondo ed è considerato un unicum al mondo nella letteratura della cardiologia pediatrica, per come è stato trattato e per il buon esito del trattamento.

Lo studio ha preso in esame la storia medica di un bambino di 4 anni, precedentemente sano, ricoverato per febbre, congiuntivite e rush cutaneo presso l’ospedale di riferimento territoriale della propria residenza. Il tampone nasofaringeo risulta negativo, mentre gli anticorpi IgG anti SARS-Cov2 sono positivi. Infatti, circa un mese prima un suo familiare aveva contratto il Covid-19, mentre il bimbo era sempre stato asintomatico; aveva evidentemente contratto il Covid anche lui senza accorgersene, come accade spesso nei bambini, fatto che spiegherebbe la negatività al tampone. Una volta ricoverato, le condizioni si aggravano e viene per questo trasferito presso la cardiologia pediatrica dell’Azienda Ospedale/Università di Padova

Qui viene fatta diagnosi di dilatazione aneurismatica della coronaria sinistra con occlusione trombotica determinante un infarto acuto del miocardio. «Il piccolo viene trattato con successo, la notte di Natale, in terapia intensiva pediatrica, per questa grave e potenzialmente letale complicanza, con un protocollo modificato di trombolisi, utilizzato per la prima volta al mondo dai cardiologi pediatri di Padova in un bambino affetto da sindrome infiammatoria secondaria al Covid – spiega il Di Salvo. Abbiamo utilizzato un farmaco che scioglie i coaguli nel sangue, utilizzando così un protocollo mai applicato prima nei bambini affetti da Covid-19, ma usato nei pazienti pediatrici affetti dalla malattia di Kawasaki, caratterizzata da complicanze vascolari che possono interessare le arterie coronariche nei bambini.»

[safe_summary] => ) ) ) [field_date_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [value] => 2021-03-04T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_etichetta_box_lancio_news] => Array ( ) [field_img_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [fid] => 90886 [uid] => 2032 [filename] => shutterstock_133068686.jpg [uri] => public://shutterstock_133068686.jpg [filemime] => image/jpeg [filesize] => 56206 [status] => 1 [timestamp] => 1614860731 [type] => image [field_file_image_alt_text] => Array ( ) [field_file_image_title_text] => Array ( ) [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( [height] => 630 [width] => 1200 ) [height] => 630 [width] => 1200 [alt] => bambino [title] => ) ) ) [field_link_alla_news] => Array ( ) [field_link_esterno_news] => Array ( ) [field_pagina_associata] => Array ( ) [field_link_etichetta] => Array ( ) [field_abstract_news] => Array ( [und] => Array ( [0] => Array ( [value] => Uno studio padovano unico nel mondo, dimostra come l’infezione da Sars-Cov2 può presentarsi in modo serio e con complicanze importanti anche nelle bambine e nei bambini piccoli che non presentano patologie preesistenti [format] => [safe_value] => Uno studio padovano unico nel mondo, dimostra come l’infezione da Sars-Cov2 può presentarsi in modo serio e con complicanze importanti anche nelle bambine e nei bambini piccoli che non presentano patologie preesistenti ) ) ) [field_allegato_news] => Array ( ) [field_categorie_news] => Array ( [und] => Array ( [0] => Array ( [tid] => 2264 ) ) ) [field_pub_date] => Array ( [und] => Array ( [0] => Array ( [value] => 2021-03-04T00:00:00 [value2] => 2021-08-04T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_layout_news] => Array ( [und] => Array ( [0] => Array ( [value] => single ) ) ) [field_testo_opzionale_news] => Array ( ) [field_url_en_page] => Array ( ) [field_url_en_page_label] => Array ( ) [path] => Array ( [pathauto] => 1 ) [name] => francesca.forzan [picture] => 0 [data] => b:0; [num_revisions] => 2 [current_revision_id] => 348017 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [fid] => 90886 [uid] => 2032 [filename] => shutterstock_133068686.jpg [uri] => public://shutterstock_133068686.jpg [filemime] => image/jpeg [filesize] => 56206 [status] => 1 [timestamp] => 1614860731 [type] => image [field_file_image_alt_text] => Array ( ) [field_file_image_title_text] => Array ( ) [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( [height] => 630 [width] => 1200 ) [height] => 630 [width] => 1200 [alt] => bambino [title] => ) ) [#formatter] => image [0] => Array ( [#theme] => image_formatter [#item] => Array ( [fid] => 90886 [uid] => 2032 [filename] => shutterstock_133068686.jpg [uri] => public://shutterstock_133068686.jpg [filemime] => image/jpeg [filesize] => 56206 [status] => 1 [timestamp] => 1614860731 [type] => image [field_file_image_alt_text] => Array ( ) [field_file_image_title_text] => Array ( ) [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( [height] => 630 [width] => 1200 ) [height] => 630 [width] => 1200 [alt] => bambino [title] => ) [#image_style] => [#path] => ) ) [field_abstract_news] => Array ( [#theme] => field [#weight] => 0 [#title] => Abstract [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_abstract_news [#field_type] => text_long [#field_translatable] => 0 [#entity_type] => node [#bundle] => box_lancio_news [#object] => stdClass Object ( [vid] => 348017 [uid] => 2032 [title] => Sars-cov2 anche bambine e bambini sani si ammalano [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 75933 [type] => box_lancio_news [language] => it [created] => 1614860731 [changed] => 1614860747 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1614860747 [revision_uid] => 2032 [body] => Array ( [und] => Array ( [0] => Array ( [value] =>

A dimostrare che l’infezione da Sars-Cov2 può presentarsi in modo serio e con complicanze importanti anche nelle bambine e nei bambini piccoli che non presentano patologie preesistenti è uno studio coordinato dal professore Giovanni Di Salvo del Dipartimento di Salute della donna e del Bambino dell’Università di Padova (con Elena Reffo e Valentina Stritoni). Inflammatory syndrome in children associated with COVID-19 complicated by acute myocardial infarction, questo il titolo della ricerca, è stato pubblicato sull’«European Heart Journal», la più autorevole rivista cardiologica al mondo ed è considerato un unicum al mondo nella letteratura della cardiologia pediatrica, per come è stato trattato e per il buon esito del trattamento.

Lo studio ha preso in esame la storia medica di un bambino di 4 anni, precedentemente sano, ricoverato per febbre, congiuntivite e rush cutaneo presso l’ospedale di riferimento territoriale della propria residenza. Il tampone nasofaringeo risulta negativo, mentre gli anticorpi IgG anti SARS-Cov2 sono positivi. Infatti, circa un mese prima un suo familiare aveva contratto il Covid-19, mentre il bimbo era sempre stato asintomatico; aveva evidentemente contratto il Covid anche lui senza accorgersene, come accade spesso nei bambini, fatto che spiegherebbe la negatività al tampone. Una volta ricoverato, le condizioni si aggravano e viene per questo trasferito presso la cardiologia pediatrica dell’Azienda Ospedale/Università di Padova

Qui viene fatta diagnosi di dilatazione aneurismatica della coronaria sinistra con occlusione trombotica determinante un infarto acuto del miocardio. «Il piccolo viene trattato con successo, la notte di Natale, in terapia intensiva pediatrica, per questa grave e potenzialmente letale complicanza, con un protocollo modificato di trombolisi, utilizzato per la prima volta al mondo dai cardiologi pediatri di Padova in un bambino affetto da sindrome infiammatoria secondaria al Covid – spiega il Di Salvo. Abbiamo utilizzato un farmaco che scioglie i coaguli nel sangue, utilizzando così un protocollo mai applicato prima nei bambini affetti da Covid-19, ma usato nei pazienti pediatrici affetti dalla malattia di Kawasaki, caratterizzata da complicanze vascolari che possono interessare le arterie coronariche nei bambini.»

[summary] => [format] => 2 [safe_value] =>

A dimostrare che l’infezione da Sars-Cov2 può presentarsi in modo serio e con complicanze importanti anche nelle bambine e nei bambini piccoli che non presentano patologie preesistenti è uno studio coordinato dal professore Giovanni Di Salvo del Dipartimento di Salute della donna e del Bambino dell’Università di Padova (con Elena Reffo e Valentina Stritoni). Inflammatory syndrome in children associated with COVID-19 complicated by acute myocardial infarction, questo il titolo della ricerca, è stato pubblicato sull’«European Heart Journal», la più autorevole rivista cardiologica al mondo ed è considerato un unicum al mondo nella letteratura della cardiologia pediatrica, per come è stato trattato e per il buon esito del trattamento.

Lo studio ha preso in esame la storia medica di un bambino di 4 anni, precedentemente sano, ricoverato per febbre, congiuntivite e rush cutaneo presso l’ospedale di riferimento territoriale della propria residenza. Il tampone nasofaringeo risulta negativo, mentre gli anticorpi IgG anti SARS-Cov2 sono positivi. Infatti, circa un mese prima un suo familiare aveva contratto il Covid-19, mentre il bimbo era sempre stato asintomatico; aveva evidentemente contratto il Covid anche lui senza accorgersene, come accade spesso nei bambini, fatto che spiegherebbe la negatività al tampone. Una volta ricoverato, le condizioni si aggravano e viene per questo trasferito presso la cardiologia pediatrica dell’Azienda Ospedale/Università di Padova

Qui viene fatta diagnosi di dilatazione aneurismatica della coronaria sinistra con occlusione trombotica determinante un infarto acuto del miocardio. «Il piccolo viene trattato con successo, la notte di Natale, in terapia intensiva pediatrica, per questa grave e potenzialmente letale complicanza, con un protocollo modificato di trombolisi, utilizzato per la prima volta al mondo dai cardiologi pediatri di Padova in un bambino affetto da sindrome infiammatoria secondaria al Covid – spiega il Di Salvo. Abbiamo utilizzato un farmaco che scioglie i coaguli nel sangue, utilizzando così un protocollo mai applicato prima nei bambini affetti da Covid-19, ma usato nei pazienti pediatrici affetti dalla malattia di Kawasaki, caratterizzata da complicanze vascolari che possono interessare le arterie coronariche nei bambini.»

[safe_summary] => ) ) ) [field_date_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [value] => 2021-03-04T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_etichetta_box_lancio_news] => Array ( ) [field_img_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [fid] => 90886 [uid] => 2032 [filename] => shutterstock_133068686.jpg [uri] => public://shutterstock_133068686.jpg [filemime] => image/jpeg [filesize] => 56206 [status] => 1 [timestamp] => 1614860731 [type] => image [field_file_image_alt_text] => Array ( ) [field_file_image_title_text] => Array ( ) [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( [height] => 630 [width] => 1200 ) [height] => 630 [width] => 1200 [alt] => bambino [title] => ) ) ) [field_link_alla_news] => Array ( ) [field_link_esterno_news] => Array ( ) [field_pagina_associata] => Array ( ) [field_link_etichetta] => Array ( ) [field_abstract_news] => Array ( [und] => Array ( [0] => Array ( [value] => Uno studio padovano unico nel mondo, dimostra come l’infezione da Sars-Cov2 può presentarsi in modo serio e con complicanze importanti anche nelle bambine e nei bambini piccoli che non presentano patologie preesistenti [format] => [safe_value] => Uno studio padovano unico nel mondo, dimostra come l’infezione da Sars-Cov2 può presentarsi in modo serio e con complicanze importanti anche nelle bambine e nei bambini piccoli che non presentano patologie preesistenti ) ) ) [field_allegato_news] => Array ( ) [field_categorie_news] => Array ( [und] => Array ( [0] => Array ( [tid] => 2264 ) ) ) [field_pub_date] => Array ( [und] => Array ( [0] => Array ( [value] => 2021-03-04T00:00:00 [value2] => 2021-08-04T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_layout_news] => Array ( [und] => Array ( [0] => Array ( [value] => single ) ) ) [field_testo_opzionale_news] => Array ( ) [field_url_en_page] => Array ( ) [field_url_en_page_label] => Array ( ) [path] => Array ( [pathauto] => 1 ) [name] => francesca.forzan [picture] => 0 [data] => b:0; [num_revisions] => 2 [current_revision_id] => 348017 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [value] => Uno studio padovano unico nel mondo, dimostra come l’infezione da Sars-Cov2 può presentarsi in modo serio e con complicanze importanti anche nelle bambine e nei bambini piccoli che non presentano patologie preesistenti [format] => [safe_value] => Uno studio padovano unico nel mondo, dimostra come l’infezione da Sars-Cov2 può presentarsi in modo serio e con complicanze importanti anche nelle bambine e nei bambini piccoli che non presentano patologie preesistenti ) ) [#formatter] => text_default [0] => Array ( [#markup] => Uno studio padovano unico nel mondo, dimostra come l’infezione da Sars-Cov2 può presentarsi in modo serio e con complicanze importanti anche nelle bambine e nei bambini piccoli che non presentano patologie preesistenti ) ) [links] => Array ( [#theme] => links__node [#pre_render] => Array ( [0] => drupal_pre_render_links ) [#attributes] => Array ( [class] => Array ( [0] => links [1] => inline ) ) [node] => Array ( [#theme] => links__node__node [#links] => Array ( [node-readmore] => Array ( [title] => Read more about Sars-cov2 anche bambine e bambini sani si ammalano [href] => node/75933 [html] => 1 [attributes] => Array ( [rel] => tag [title] => Sars-cov2 anche bambine e bambini sani si ammalano ) ) ) [#attributes] => Array ( [class] => Array ( [0] => links [1] => inline ) ) ) ) [field_date_box_lancio_news] => Array ( [#theme] => field [#weight] => 1 [#title] => Data [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_date_box_lancio_news [#field_type] => date [#field_translatable] => 0 [#entity_type] => node [#bundle] => box_lancio_news [#object] => stdClass Object ( [vid] => 348017 [uid] => 2032 [title] => Sars-cov2 anche bambine e bambini sani si ammalano [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 75933 [type] => box_lancio_news [language] => it [created] => 1614860731 [changed] => 1614860747 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1614860747 [revision_uid] => 2032 [body] => Array ( [und] => Array ( [0] => Array ( [value] =>

A dimostrare che l’infezione da Sars-Cov2 può presentarsi in modo serio e con complicanze importanti anche nelle bambine e nei bambini piccoli che non presentano patologie preesistenti è uno studio coordinato dal professore Giovanni Di Salvo del Dipartimento di Salute della donna e del Bambino dell’Università di Padova (con Elena Reffo e Valentina Stritoni). Inflammatory syndrome in children associated with COVID-19 complicated by acute myocardial infarction, questo il titolo della ricerca, è stato pubblicato sull’«European Heart Journal», la più autorevole rivista cardiologica al mondo ed è considerato un unicum al mondo nella letteratura della cardiologia pediatrica, per come è stato trattato e per il buon esito del trattamento.

Lo studio ha preso in esame la storia medica di un bambino di 4 anni, precedentemente sano, ricoverato per febbre, congiuntivite e rush cutaneo presso l’ospedale di riferimento territoriale della propria residenza. Il tampone nasofaringeo risulta negativo, mentre gli anticorpi IgG anti SARS-Cov2 sono positivi. Infatti, circa un mese prima un suo familiare aveva contratto il Covid-19, mentre il bimbo era sempre stato asintomatico; aveva evidentemente contratto il Covid anche lui senza accorgersene, come accade spesso nei bambini, fatto che spiegherebbe la negatività al tampone. Una volta ricoverato, le condizioni si aggravano e viene per questo trasferito presso la cardiologia pediatrica dell’Azienda Ospedale/Università di Padova

Qui viene fatta diagnosi di dilatazione aneurismatica della coronaria sinistra con occlusione trombotica determinante un infarto acuto del miocardio. «Il piccolo viene trattato con successo, la notte di Natale, in terapia intensiva pediatrica, per questa grave e potenzialmente letale complicanza, con un protocollo modificato di trombolisi, utilizzato per la prima volta al mondo dai cardiologi pediatri di Padova in un bambino affetto da sindrome infiammatoria secondaria al Covid – spiega il Di Salvo. Abbiamo utilizzato un farmaco che scioglie i coaguli nel sangue, utilizzando così un protocollo mai applicato prima nei bambini affetti da Covid-19, ma usato nei pazienti pediatrici affetti dalla malattia di Kawasaki, caratterizzata da complicanze vascolari che possono interessare le arterie coronariche nei bambini.»

[summary] => [format] => 2 [safe_value] =>

A dimostrare che l’infezione da Sars-Cov2 può presentarsi in modo serio e con complicanze importanti anche nelle bambine e nei bambini piccoli che non presentano patologie preesistenti è uno studio coordinato dal professore Giovanni Di Salvo del Dipartimento di Salute della donna e del Bambino dell’Università di Padova (con Elena Reffo e Valentina Stritoni). Inflammatory syndrome in children associated with COVID-19 complicated by acute myocardial infarction, questo il titolo della ricerca, è stato pubblicato sull’«European Heart Journal», la più autorevole rivista cardiologica al mondo ed è considerato un unicum al mondo nella letteratura della cardiologia pediatrica, per come è stato trattato e per il buon esito del trattamento.

Lo studio ha preso in esame la storia medica di un bambino di 4 anni, precedentemente sano, ricoverato per febbre, congiuntivite e rush cutaneo presso l’ospedale di riferimento territoriale della propria residenza. Il tampone nasofaringeo risulta negativo, mentre gli anticorpi IgG anti SARS-Cov2 sono positivi. Infatti, circa un mese prima un suo familiare aveva contratto il Covid-19, mentre il bimbo era sempre stato asintomatico; aveva evidentemente contratto il Covid anche lui senza accorgersene, come accade spesso nei bambini, fatto che spiegherebbe la negatività al tampone. Una volta ricoverato, le condizioni si aggravano e viene per questo trasferito presso la cardiologia pediatrica dell’Azienda Ospedale/Università di Padova

Qui viene fatta diagnosi di dilatazione aneurismatica della coronaria sinistra con occlusione trombotica determinante un infarto acuto del miocardio. «Il piccolo viene trattato con successo, la notte di Natale, in terapia intensiva pediatrica, per questa grave e potenzialmente letale complicanza, con un protocollo modificato di trombolisi, utilizzato per la prima volta al mondo dai cardiologi pediatri di Padova in un bambino affetto da sindrome infiammatoria secondaria al Covid – spiega il Di Salvo. Abbiamo utilizzato un farmaco che scioglie i coaguli nel sangue, utilizzando così un protocollo mai applicato prima nei bambini affetti da Covid-19, ma usato nei pazienti pediatrici affetti dalla malattia di Kawasaki, caratterizzata da complicanze vascolari che possono interessare le arterie coronariche nei bambini.»

[safe_summary] => ) ) ) [field_date_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [value] => 2021-03-04T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_etichetta_box_lancio_news] => Array ( ) [field_img_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [fid] => 90886 [uid] => 2032 [filename] => shutterstock_133068686.jpg [uri] => public://shutterstock_133068686.jpg [filemime] => image/jpeg [filesize] => 56206 [status] => 1 [timestamp] => 1614860731 [type] => image [field_file_image_alt_text] => Array ( ) [field_file_image_title_text] => Array ( ) [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( [height] => 630 [width] => 1200 ) [height] => 630 [width] => 1200 [alt] => bambino [title] => ) ) ) [field_link_alla_news] => Array ( ) [field_link_esterno_news] => Array ( ) [field_pagina_associata] => Array ( ) [field_link_etichetta] => Array ( ) [field_abstract_news] => Array ( [und] => Array ( [0] => Array ( [value] => Uno studio padovano unico nel mondo, dimostra come l’infezione da Sars-Cov2 può presentarsi in modo serio e con complicanze importanti anche nelle bambine e nei bambini piccoli che non presentano patologie preesistenti [format] => [safe_value] => Uno studio padovano unico nel mondo, dimostra come l’infezione da Sars-Cov2 può presentarsi in modo serio e con complicanze importanti anche nelle bambine e nei bambini piccoli che non presentano patologie preesistenti ) ) ) [field_allegato_news] => Array ( ) [field_categorie_news] => Array ( [und] => Array ( [0] => Array ( [tid] => 2264 ) ) ) [field_pub_date] => Array ( [und] => Array ( [0] => Array ( [value] => 2021-03-04T00:00:00 [value2] => 2021-08-04T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_layout_news] => Array ( [und] => Array ( [0] => Array ( [value] => single ) ) ) [field_testo_opzionale_news] => Array ( ) [field_url_en_page] => Array ( ) [field_url_en_page_label] => Array ( ) [path] => Array ( [pathauto] => 1 ) [name] => francesca.forzan [picture] => 0 [data] => b:0; [num_revisions] => 2 [current_revision_id] => 348017 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [value] => 2021-03-04T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) [#formatter] => date_default [0] => Array ( [#markup] => Gio, 04/03/2021 ) ) )

SERM drug therapy to counter SARS-CoV-2 infection and virus development

Array ( [field_link_esterno_news] => Array ( [#theme] => field [#weight] => -1 [#title] => Link esterno news [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_link_esterno_news [#field_type] => text_long [#field_translatable] => 0 [#entity_type] => node [#bundle] => box_lancio_news [#object] => stdClass Object ( [vid] => 348014 [uid] => 2032 [title] => SERM drug therapy to counter SARS-CoV-2 infection and virus development [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 75932 [type] => box_lancio_news [language] => it [created] => 1614859174 [changed] => 1614859174 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1614859174 [revision_uid] => 2032 [body] => Array ( [und] => Array ( [0] => Array ( [value] =>

Published in the scientific journal ‘Annals of Oncology’, the paper entitled Clinical outcome of SARS-CoV-2 infection in breast and ovarian cancer patients underwent anti-estrogenic therapy was authored by researchers Monica Montopoli (VIMM-University of Padua) and Arianna Calcinotto (IOR of Bellinzona). The research demonstrates how SERM drugs (Selective Estrogen Receptor Modulators) could possibly counteract SARS-CoV-2 infection and subsequent virus development. Carried out in close collaboration between VIMM-University of Padua, the Veneto Cancer Registry and the IOR of Bellinzona, the study examined 51,060 women from the Veneto Region who have been tested for the SARS-CoV-2 infection.

Building on the work and research carried out at VIMM last year that showed patients with prostate cancer treated with androgen deprivation therapies (ADT) demonstrated a lower risk of infection and development of Covid-19 than patients with untreated prostate cancer. The study focused on the possible role of steroid hormones in the Covid-19 therapeutic strategy.

The study investigates how sex hormones influence those infected with Covid-19. Sex hormones play a role in regulating the immune system, which then effects proteins involved in SARS Cov-2 infection, such as ACE2 and TMPRSS differently. Using the sample of women tested, there was a reduced prevalence of infection in patients undergoing hormone-dependent tumors SERM therapy (Selective Estrogen Receptor Modulators). This suggests an off-target effect played by SERMs that potentially involves an alteration in the mechanism of between the virus and the host cell, identifying a possible clinical use in the treatment of COVID-19 patients.

The results, in line with the recent discovery developed by Exscalate4CoV, the public-private consortium supported by the European Commission’s Horizon 2020 call, provides for an efficacy of raloxifene as a potential drug against COVID-19 that will be further validated by a larger cohort of women infected with SARS-Cov-2 and corrected for several variables.

The Associated Investigator from VIMM, Dr Monica Montopoli, states, "In order to validate the hypothesis that hormone regulation shows implicating in the clinical outcome of COVID-19 patients, we evaluated the prevalence of SARS-CoV-2 infection, hospitalization, and death in women with hormone-dependent tumors being treated with anti-estrogen therapy. Although a larger sample and further molecular studies to better understand the mechanism and protective effect observed in females being treated with SERMs is needed, the study may identify a possible way to prevent or mitigate the effects of the virus.”

[summary] => [format] => 2 [safe_value] =>

Published in the scientific journal ‘Annals of Oncology’, the paper entitled Clinical outcome of SARS-CoV-2 infection in breast and ovarian cancer patients underwent anti-estrogenic therapy was authored by researchers Monica Montopoli (VIMM-University of Padua) and Arianna Calcinotto (IOR of Bellinzona). The research demonstrates how SERM drugs (Selective Estrogen Receptor Modulators) could possibly counteract SARS-CoV-2 infection and subsequent virus development. Carried out in close collaboration between VIMM-University of Padua, the Veneto Cancer Registry and the IOR of Bellinzona, the study examined 51,060 women from the Veneto Region who have been tested for the SARS-CoV-2 infection.

Building on the work and research carried out at VIMM last year that showed patients with prostate cancer treated with androgen deprivation therapies (ADT) demonstrated a lower risk of infection and development of Covid-19 than patients with untreated prostate cancer. The study focused on the possible role of steroid hormones in the Covid-19 therapeutic strategy.

The study investigates how sex hormones influence those infected with Covid-19. Sex hormones play a role in regulating the immune system, which then effects proteins involved in SARS Cov-2 infection, such as ACE2 and TMPRSS differently. Using the sample of women tested, there was a reduced prevalence of infection in patients undergoing hormone-dependent tumors SERM therapy (Selective Estrogen Receptor Modulators). This suggests an off-target effect played by SERMs that potentially involves an alteration in the mechanism of between the virus and the host cell, identifying a possible clinical use in the treatment of COVID-19 patients.

The results, in line with the recent discovery developed by Exscalate4CoV, the public-private consortium supported by the European Commission’s Horizon 2020 call, provides for an efficacy of raloxifene as a potential drug against COVID-19 that will be further validated by a larger cohort of women infected with SARS-Cov-2 and corrected for several variables.

The Associated Investigator from VIMM, Dr Monica Montopoli, states, "In order to validate the hypothesis that hormone regulation shows implicating in the clinical outcome of COVID-19 patients, we evaluated the prevalence of SARS-CoV-2 infection, hospitalization, and death in women with hormone-dependent tumors being treated with anti-estrogen therapy. Although a larger sample and further molecular studies to better understand the mechanism and protective effect observed in females being treated with SERMs is needed, the study may identify a possible way to prevent or mitigate the effects of the virus.”

[safe_summary] => ) ) ) [field_date_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [value] => 2021-03-04T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_etichetta_box_lancio_news] => Array ( ) [field_img_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [fid] => 90881 [uid] => 2032 [filename] => n_ospedale_letto.jpg [uri] => public://n_ospedale_letto.jpg [filemime] => image/jpeg [filesize] => 51038 [status] => 1 [timestamp] => 1614859174 [type] => image [field_file_image_alt_text] => Array ( ) [field_file_image_title_text] => Array ( ) [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( [height] => 630 [width] => 1200 ) [height] => 630 [width] => 1200 [alt] => hospital [title] => ) ) ) [field_link_alla_news] => Array ( ) [field_link_esterno_news] => Array ( [und] => Array ( [0] => Array ( [value] => [format] => [safe_value] => ) ) ) [field_pagina_associata] => Array ( ) [field_link_etichetta] => Array ( ) [field_abstract_news] => Array ( [und] => Array ( [0] => Array ( [value] => The collaborative research conducted between VIMM, the University of Padua, the Veneto Cancer Registry, and the Institute of Oncology Research (IOR) of Bellinzona shows how anti-estrogen drugs (SERMs) administered to women for breast cancer treatment blocks Covid-19. [format] => [safe_value] => The collaborative research conducted between VIMM, the University of Padua, the Veneto Cancer Registry, and the Institute of Oncology Research (IOR) of Bellinzona shows how anti-estrogen drugs (SERMs) administered to women for breast cancer treatment blocks Covid-19. ) ) ) [field_allegato_news] => Array ( ) [field_categorie_news] => Array ( [und] => Array ( [0] => Array ( [tid] => 2296 ) ) ) [field_pub_date] => Array ( [und] => Array ( [0] => Array ( [value] => 2021-03-04T00:00:00 [value2] => 2021-12-04T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_layout_news] => Array ( [und] => Array ( [0] => Array ( [value] => single ) ) ) [field_testo_opzionale_news] => Array ( ) [field_url_en_page] => Array ( ) [field_url_en_page_label] => Array ( ) [path] => Array ( [pathauto] => 1 ) [name] => francesca.forzan [picture] => 0 [data] => b:0; [num_revisions] => 1 [current_revision_id] => 348014 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [value] => [format] => [safe_value] => ) ) [#formatter] => text_default [0] => Array ( [#markup] => ) ) [body] => Array ( [#theme] => field [#weight] => 0 [#title] => Body [#access] => 1 [#label_display] => hidden [#view_mode] => teaser [#language] => und [#field_name] => body [#field_type] => text_with_summary [#field_translatable] => 0 [#entity_type] => node [#bundle] => box_lancio_news [#object] => stdClass Object ( [vid] => 348014 [uid] => 2032 [title] => SERM drug therapy to counter SARS-CoV-2 infection and virus development [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 75932 [type] => box_lancio_news [language] => it [created] => 1614859174 [changed] => 1614859174 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1614859174 [revision_uid] => 2032 [body] => Array ( [und] => Array ( [0] => Array ( [value] =>

Published in the scientific journal ‘Annals of Oncology’, the paper entitled Clinical outcome of SARS-CoV-2 infection in breast and ovarian cancer patients underwent anti-estrogenic therapy was authored by researchers Monica Montopoli (VIMM-University of Padua) and Arianna Calcinotto (IOR of Bellinzona). The research demonstrates how SERM drugs (Selective Estrogen Receptor Modulators) could possibly counteract SARS-CoV-2 infection and subsequent virus development. Carried out in close collaboration between VIMM-University of Padua, the Veneto Cancer Registry and the IOR of Bellinzona, the study examined 51,060 women from the Veneto Region who have been tested for the SARS-CoV-2 infection.

Building on the work and research carried out at VIMM last year that showed patients with prostate cancer treated with androgen deprivation therapies (ADT) demonstrated a lower risk of infection and development of Covid-19 than patients with untreated prostate cancer. The study focused on the possible role of steroid hormones in the Covid-19 therapeutic strategy.

The study investigates how sex hormones influence those infected with Covid-19. Sex hormones play a role in regulating the immune system, which then effects proteins involved in SARS Cov-2 infection, such as ACE2 and TMPRSS differently. Using the sample of women tested, there was a reduced prevalence of infection in patients undergoing hormone-dependent tumors SERM therapy (Selective Estrogen Receptor Modulators). This suggests an off-target effect played by SERMs that potentially involves an alteration in the mechanism of between the virus and the host cell, identifying a possible clinical use in the treatment of COVID-19 patients.

The results, in line with the recent discovery developed by Exscalate4CoV, the public-private consortium supported by the European Commission’s Horizon 2020 call, provides for an efficacy of raloxifene as a potential drug against COVID-19 that will be further validated by a larger cohort of women infected with SARS-Cov-2 and corrected for several variables.

The Associated Investigator from VIMM, Dr Monica Montopoli, states, "In order to validate the hypothesis that hormone regulation shows implicating in the clinical outcome of COVID-19 patients, we evaluated the prevalence of SARS-CoV-2 infection, hospitalization, and death in women with hormone-dependent tumors being treated with anti-estrogen therapy. Although a larger sample and further molecular studies to better understand the mechanism and protective effect observed in females being treated with SERMs is needed, the study may identify a possible way to prevent or mitigate the effects of the virus.”

[summary] => [format] => 2 [safe_value] =>

Published in the scientific journal ‘Annals of Oncology’, the paper entitled Clinical outcome of SARS-CoV-2 infection in breast and ovarian cancer patients underwent anti-estrogenic therapy was authored by researchers Monica Montopoli (VIMM-University of Padua) and Arianna Calcinotto (IOR of Bellinzona). The research demonstrates how SERM drugs (Selective Estrogen Receptor Modulators) could possibly counteract SARS-CoV-2 infection and subsequent virus development. Carried out in close collaboration between VIMM-University of Padua, the Veneto Cancer Registry and the IOR of Bellinzona, the study examined 51,060 women from the Veneto Region who have been tested for the SARS-CoV-2 infection.

Building on the work and research carried out at VIMM last year that showed patients with prostate cancer treated with androgen deprivation therapies (ADT) demonstrated a lower risk of infection and development of Covid-19 than patients with untreated prostate cancer. The study focused on the possible role of steroid hormones in the Covid-19 therapeutic strategy.

The study investigates how sex hormones influence those infected with Covid-19. Sex hormones play a role in regulating the immune system, which then effects proteins involved in SARS Cov-2 infection, such as ACE2 and TMPRSS differently. Using the sample of women tested, there was a reduced prevalence of infection in patients undergoing hormone-dependent tumors SERM therapy (Selective Estrogen Receptor Modulators). This suggests an off-target effect played by SERMs that potentially involves an alteration in the mechanism of between the virus and the host cell, identifying a possible clinical use in the treatment of COVID-19 patients.

The results, in line with the recent discovery developed by Exscalate4CoV, the public-private consortium supported by the European Commission’s Horizon 2020 call, provides for an efficacy of raloxifene as a potential drug against COVID-19 that will be further validated by a larger cohort of women infected with SARS-Cov-2 and corrected for several variables.

The Associated Investigator from VIMM, Dr Monica Montopoli, states, "In order to validate the hypothesis that hormone regulation shows implicating in the clinical outcome of COVID-19 patients, we evaluated the prevalence of SARS-CoV-2 infection, hospitalization, and death in women with hormone-dependent tumors being treated with anti-estrogen therapy. Although a larger sample and further molecular studies to better understand the mechanism and protective effect observed in females being treated with SERMs is needed, the study may identify a possible way to prevent or mitigate the effects of the virus.”

[safe_summary] => ) ) ) [field_date_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [value] => 2021-03-04T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_etichetta_box_lancio_news] => Array ( ) [field_img_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [fid] => 90881 [uid] => 2032 [filename] => n_ospedale_letto.jpg [uri] => public://n_ospedale_letto.jpg [filemime] => image/jpeg [filesize] => 51038 [status] => 1 [timestamp] => 1614859174 [type] => image [field_file_image_alt_text] => Array ( ) [field_file_image_title_text] => Array ( ) [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( [height] => 630 [width] => 1200 ) [height] => 630 [width] => 1200 [alt] => hospital [title] => ) ) ) [field_link_alla_news] => Array ( ) [field_link_esterno_news] => Array ( [und] => Array ( [0] => Array ( [value] => [format] => [safe_value] => ) ) ) [field_pagina_associata] => Array ( ) [field_link_etichetta] => Array ( ) [field_abstract_news] => Array ( [und] => Array ( [0] => Array ( [value] => The collaborative research conducted between VIMM, the University of Padua, the Veneto Cancer Registry, and the Institute of Oncology Research (IOR) of Bellinzona shows how anti-estrogen drugs (SERMs) administered to women for breast cancer treatment blocks Covid-19. [format] => [safe_value] => The collaborative research conducted between VIMM, the University of Padua, the Veneto Cancer Registry, and the Institute of Oncology Research (IOR) of Bellinzona shows how anti-estrogen drugs (SERMs) administered to women for breast cancer treatment blocks Covid-19. ) ) ) [field_allegato_news] => Array ( ) [field_categorie_news] => Array ( [und] => Array ( [0] => Array ( [tid] => 2296 ) ) ) [field_pub_date] => Array ( [und] => Array ( [0] => Array ( [value] => 2021-03-04T00:00:00 [value2] => 2021-12-04T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_layout_news] => Array ( [und] => Array ( [0] => Array ( [value] => single ) ) ) [field_testo_opzionale_news] => Array ( ) [field_url_en_page] => Array ( ) [field_url_en_page_label] => Array ( ) [path] => Array ( [pathauto] => 1 ) [name] => francesca.forzan [picture] => 0 [data] => b:0; [num_revisions] => 1 [current_revision_id] => 348014 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [value] =>

Published in the scientific journal ‘Annals of Oncology’, the paper entitled Clinical outcome of SARS-CoV-2 infection in breast and ovarian cancer patients underwent anti-estrogenic therapy was authored by researchers Monica Montopoli (VIMM-University of Padua) and Arianna Calcinotto (IOR of Bellinzona). The research demonstrates how SERM drugs (Selective Estrogen Receptor Modulators) could possibly counteract SARS-CoV-2 infection and subsequent virus development. Carried out in close collaboration between VIMM-University of Padua, the Veneto Cancer Registry and the IOR of Bellinzona, the study examined 51,060 women from the Veneto Region who have been tested for the SARS-CoV-2 infection.

Building on the work and research carried out at VIMM last year that showed patients with prostate cancer treated with androgen deprivation therapies (ADT) demonstrated a lower risk of infection and development of Covid-19 than patients with untreated prostate cancer. The study focused on the possible role of steroid hormones in the Covid-19 therapeutic strategy.

The study investigates how sex hormones influence those infected with Covid-19. Sex hormones play a role in regulating the immune system, which then effects proteins involved in SARS Cov-2 infection, such as ACE2 and TMPRSS differently. Using the sample of women tested, there was a reduced prevalence of infection in patients undergoing hormone-dependent tumors SERM therapy (Selective Estrogen Receptor Modulators). This suggests an off-target effect played by SERMs that potentially involves an alteration in the mechanism of between the virus and the host cell, identifying a possible clinical use in the treatment of COVID-19 patients.

The results, in line with the recent discovery developed by Exscalate4CoV, the public-private consortium supported by the European Commission’s Horizon 2020 call, provides for an efficacy of raloxifene as a potential drug against COVID-19 that will be further validated by a larger cohort of women infected with SARS-Cov-2 and corrected for several variables.

The Associated Investigator from VIMM, Dr Monica Montopoli, states, "In order to validate the hypothesis that hormone regulation shows implicating in the clinical outcome of COVID-19 patients, we evaluated the prevalence of SARS-CoV-2 infection, hospitalization, and death in women with hormone-dependent tumors being treated with anti-estrogen therapy. Although a larger sample and further molecular studies to better understand the mechanism and protective effect observed in females being treated with SERMs is needed, the study may identify a possible way to prevent or mitigate the effects of the virus.”

[summary] => [format] => 2 [safe_value] =>

Published in the scientific journal ‘Annals of Oncology’, the paper entitled Clinical outcome of SARS-CoV-2 infection in breast and ovarian cancer patients underwent anti-estrogenic therapy was authored by researchers Monica Montopoli (VIMM-University of Padua) and Arianna Calcinotto (IOR of Bellinzona). The research demonstrates how SERM drugs (Selective Estrogen Receptor Modulators) could possibly counteract SARS-CoV-2 infection and subsequent virus development. Carried out in close collaboration between VIMM-University of Padua, the Veneto Cancer Registry and the IOR of Bellinzona, the study examined 51,060 women from the Veneto Region who have been tested for the SARS-CoV-2 infection.

Building on the work and research carried out at VIMM last year that showed patients with prostate cancer treated with androgen deprivation therapies (ADT) demonstrated a lower risk of infection and development of Covid-19 than patients with untreated prostate cancer. The study focused on the possible role of steroid hormones in the Covid-19 therapeutic strategy.

The study investigates how sex hormones influence those infected with Covid-19. Sex hormones play a role in regulating the immune system, which then effects proteins involved in SARS Cov-2 infection, such as ACE2 and TMPRSS differently. Using the sample of women tested, there was a reduced prevalence of infection in patients undergoing hormone-dependent tumors SERM therapy (Selective Estrogen Receptor Modulators). This suggests an off-target effect played by SERMs that potentially involves an alteration in the mechanism of between the virus and the host cell, identifying a possible clinical use in the treatment of COVID-19 patients.

The results, in line with the recent discovery developed by Exscalate4CoV, the public-private consortium supported by the European Commission’s Horizon 2020 call, provides for an efficacy of raloxifene as a potential drug against COVID-19 that will be further validated by a larger cohort of women infected with SARS-Cov-2 and corrected for several variables.

The Associated Investigator from VIMM, Dr Monica Montopoli, states, "In order to validate the hypothesis that hormone regulation shows implicating in the clinical outcome of COVID-19 patients, we evaluated the prevalence of SARS-CoV-2 infection, hospitalization, and death in women with hormone-dependent tumors being treated with anti-estrogen therapy. Although a larger sample and further molecular studies to better understand the mechanism and protective effect observed in females being treated with SERMs is needed, the study may identify a possible way to prevent or mitigate the effects of the virus.”

[safe_summary] => ) ) [#formatter] => text_summary_or_trimmed [0] => Array ( [#markup] =>

Published in the scientific journal ‘Annals of Oncology’, the paper entitled Clinical outcome of SARS-CoV-2 infection in breast and ovarian cancer patients underwent anti-estrogenic therapy was authored by researchers Monica Montopoli (VIMM-University of Padua) and Arianna Calcinotto (IOR of Bellinzona). The research demonstrates how SERM drugs (Selective Estrogen Receptor Modulators) could possibly counteract SARS-CoV-2 infection and subsequent virus development.

) ) [field_img_box_lancio_news] => Array ( [#theme] => field [#weight] => 0 [#title] => Immagine [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_img_box_lancio_news [#field_type] => image [#field_translatable] => 0 [#entity_type] => node [#bundle] => box_lancio_news [#object] => stdClass Object ( [vid] => 348014 [uid] => 2032 [title] => SERM drug therapy to counter SARS-CoV-2 infection and virus development [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 75932 [type] => box_lancio_news [language] => it [created] => 1614859174 [changed] => 1614859174 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1614859174 [revision_uid] => 2032 [body] => Array ( [und] => Array ( [0] => Array ( [value] =>

Published in the scientific journal ‘Annals of Oncology’, the paper entitled Clinical outcome of SARS-CoV-2 infection in breast and ovarian cancer patients underwent anti-estrogenic therapy was authored by researchers Monica Montopoli (VIMM-University of Padua) and Arianna Calcinotto (IOR of Bellinzona). The research demonstrates how SERM drugs (Selective Estrogen Receptor Modulators) could possibly counteract SARS-CoV-2 infection and subsequent virus development. Carried out in close collaboration between VIMM-University of Padua, the Veneto Cancer Registry and the IOR of Bellinzona, the study examined 51,060 women from the Veneto Region who have been tested for the SARS-CoV-2 infection.

Building on the work and research carried out at VIMM last year that showed patients with prostate cancer treated with androgen deprivation therapies (ADT) demonstrated a lower risk of infection and development of Covid-19 than patients with untreated prostate cancer. The study focused on the possible role of steroid hormones in the Covid-19 therapeutic strategy.

The study investigates how sex hormones influence those infected with Covid-19. Sex hormones play a role in regulating the immune system, which then effects proteins involved in SARS Cov-2 infection, such as ACE2 and TMPRSS differently. Using the sample of women tested, there was a reduced prevalence of infection in patients undergoing hormone-dependent tumors SERM therapy (Selective Estrogen Receptor Modulators). This suggests an off-target effect played by SERMs that potentially involves an alteration in the mechanism of between the virus and the host cell, identifying a possible clinical use in the treatment of COVID-19 patients.

The results, in line with the recent discovery developed by Exscalate4CoV, the public-private consortium supported by the European Commission’s Horizon 2020 call, provides for an efficacy of raloxifene as a potential drug against COVID-19 that will be further validated by a larger cohort of women infected with SARS-Cov-2 and corrected for several variables.

The Associated Investigator from VIMM, Dr Monica Montopoli, states, "In order to validate the hypothesis that hormone regulation shows implicating in the clinical outcome of COVID-19 patients, we evaluated the prevalence of SARS-CoV-2 infection, hospitalization, and death in women with hormone-dependent tumors being treated with anti-estrogen therapy. Although a larger sample and further molecular studies to better understand the mechanism and protective effect observed in females being treated with SERMs is needed, the study may identify a possible way to prevent or mitigate the effects of the virus.”

[summary] => [format] => 2 [safe_value] =>

Published in the scientific journal ‘Annals of Oncology’, the paper entitled Clinical outcome of SARS-CoV-2 infection in breast and ovarian cancer patients underwent anti-estrogenic therapy was authored by researchers Monica Montopoli (VIMM-University of Padua) and Arianna Calcinotto (IOR of Bellinzona). The research demonstrates how SERM drugs (Selective Estrogen Receptor Modulators) could possibly counteract SARS-CoV-2 infection and subsequent virus development. Carried out in close collaboration between VIMM-University of Padua, the Veneto Cancer Registry and the IOR of Bellinzona, the study examined 51,060 women from the Veneto Region who have been tested for the SARS-CoV-2 infection.

Building on the work and research carried out at VIMM last year that showed patients with prostate cancer treated with androgen deprivation therapies (ADT) demonstrated a lower risk of infection and development of Covid-19 than patients with untreated prostate cancer. The study focused on the possible role of steroid hormones in the Covid-19 therapeutic strategy.

The study investigates how sex hormones influence those infected with Covid-19. Sex hormones play a role in regulating the immune system, which then effects proteins involved in SARS Cov-2 infection, such as ACE2 and TMPRSS differently. Using the sample of women tested, there was a reduced prevalence of infection in patients undergoing hormone-dependent tumors SERM therapy (Selective Estrogen Receptor Modulators). This suggests an off-target effect played by SERMs that potentially involves an alteration in the mechanism of between the virus and the host cell, identifying a possible clinical use in the treatment of COVID-19 patients.

The results, in line with the recent discovery developed by Exscalate4CoV, the public-private consortium supported by the European Commission’s Horizon 2020 call, provides for an efficacy of raloxifene as a potential drug against COVID-19 that will be further validated by a larger cohort of women infected with SARS-Cov-2 and corrected for several variables.

The Associated Investigator from VIMM, Dr Monica Montopoli, states, "In order to validate the hypothesis that hormone regulation shows implicating in the clinical outcome of COVID-19 patients, we evaluated the prevalence of SARS-CoV-2 infection, hospitalization, and death in women with hormone-dependent tumors being treated with anti-estrogen therapy. Although a larger sample and further molecular studies to better understand the mechanism and protective effect observed in females being treated with SERMs is needed, the study may identify a possible way to prevent or mitigate the effects of the virus.”

[safe_summary] => ) ) ) [field_date_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [value] => 2021-03-04T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_etichetta_box_lancio_news] => Array ( ) [field_img_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [fid] => 90881 [uid] => 2032 [filename] => n_ospedale_letto.jpg [uri] => public://n_ospedale_letto.jpg [filemime] => image/jpeg [filesize] => 51038 [status] => 1 [timestamp] => 1614859174 [type] => image [field_file_image_alt_text] => Array ( ) [field_file_image_title_text] => Array ( ) [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( [height] => 630 [width] => 1200 ) [height] => 630 [width] => 1200 [alt] => hospital [title] => ) ) ) [field_link_alla_news] => Array ( ) [field_link_esterno_news] => Array ( [und] => Array ( [0] => Array ( [value] => [format] => [safe_value] => ) ) ) [field_pagina_associata] => Array ( ) [field_link_etichetta] => Array ( ) [field_abstract_news] => Array ( [und] => Array ( [0] => Array ( [value] => The collaborative research conducted between VIMM, the University of Padua, the Veneto Cancer Registry, and the Institute of Oncology Research (IOR) of Bellinzona shows how anti-estrogen drugs (SERMs) administered to women for breast cancer treatment blocks Covid-19. [format] => [safe_value] => The collaborative research conducted between VIMM, the University of Padua, the Veneto Cancer Registry, and the Institute of Oncology Research (IOR) of Bellinzona shows how anti-estrogen drugs (SERMs) administered to women for breast cancer treatment blocks Covid-19. ) ) ) [field_allegato_news] => Array ( ) [field_categorie_news] => Array ( [und] => Array ( [0] => Array ( [tid] => 2296 ) ) ) [field_pub_date] => Array ( [und] => Array ( [0] => Array ( [value] => 2021-03-04T00:00:00 [value2] => 2021-12-04T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_layout_news] => Array ( [und] => Array ( [0] => Array ( [value] => single ) ) ) [field_testo_opzionale_news] => Array ( ) [field_url_en_page] => Array ( ) [field_url_en_page_label] => Array ( ) [path] => Array ( [pathauto] => 1 ) [name] => francesca.forzan [picture] => 0 [data] => b:0; [num_revisions] => 1 [current_revision_id] => 348014 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [fid] => 90881 [uid] => 2032 [filename] => n_ospedale_letto.jpg [uri] => public://n_ospedale_letto.jpg [filemime] => image/jpeg [filesize] => 51038 [status] => 1 [timestamp] => 1614859174 [type] => image [field_file_image_alt_text] => Array ( ) [field_file_image_title_text] => Array ( ) [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( [height] => 630 [width] => 1200 ) [height] => 630 [width] => 1200 [alt] => hospital [title] => ) ) [#formatter] => image [0] => Array ( [#theme] => image_formatter [#item] => Array ( [fid] => 90881 [uid] => 2032 [filename] => n_ospedale_letto.jpg [uri] => public://n_ospedale_letto.jpg [filemime] => image/jpeg [filesize] => 51038 [status] => 1 [timestamp] => 1614859174 [type] => image [field_file_image_alt_text] => Array ( ) [field_file_image_title_text] => Array ( ) [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( [height] => 630 [width] => 1200 ) [height] => 630 [width] => 1200 [alt] => hospital [title] => ) [#image_style] => [#path] => ) ) [field_abstract_news] => Array ( [#theme] => field [#weight] => 0 [#title] => Abstract [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_abstract_news [#field_type] => text_long [#field_translatable] => 0 [#entity_type] => node [#bundle] => box_lancio_news [#object] => stdClass Object ( [vid] => 348014 [uid] => 2032 [title] => SERM drug therapy to counter SARS-CoV-2 infection and virus development [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 75932 [type] => box_lancio_news [language] => it [created] => 1614859174 [changed] => 1614859174 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1614859174 [revision_uid] => 2032 [body] => Array ( [und] => Array ( [0] => Array ( [value] =>

Published in the scientific journal ‘Annals of Oncology’, the paper entitled Clinical outcome of SARS-CoV-2 infection in breast and ovarian cancer patients underwent anti-estrogenic therapy was authored by researchers Monica Montopoli (VIMM-University of Padua) and Arianna Calcinotto (IOR of Bellinzona). The research demonstrates how SERM drugs (Selective Estrogen Receptor Modulators) could possibly counteract SARS-CoV-2 infection and subsequent virus development. Carried out in close collaboration between VIMM-University of Padua, the Veneto Cancer Registry and the IOR of Bellinzona, the study examined 51,060 women from the Veneto Region who have been tested for the SARS-CoV-2 infection.

Building on the work and research carried out at VIMM last year that showed patients with prostate cancer treated with androgen deprivation therapies (ADT) demonstrated a lower risk of infection and development of Covid-19 than patients with untreated prostate cancer. The study focused on the possible role of steroid hormones in the Covid-19 therapeutic strategy.

The study investigates how sex hormones influence those infected with Covid-19. Sex hormones play a role in regulating the immune system, which then effects proteins involved in SARS Cov-2 infection, such as ACE2 and TMPRSS differently. Using the sample of women tested, there was a reduced prevalence of infection in patients undergoing hormone-dependent tumors SERM therapy (Selective Estrogen Receptor Modulators). This suggests an off-target effect played by SERMs that potentially involves an alteration in the mechanism of between the virus and the host cell, identifying a possible clinical use in the treatment of COVID-19 patients.

The results, in line with the recent discovery developed by Exscalate4CoV, the public-private consortium supported by the European Commission’s Horizon 2020 call, provides for an efficacy of raloxifene as a potential drug against COVID-19 that will be further validated by a larger cohort of women infected with SARS-Cov-2 and corrected for several variables.

The Associated Investigator from VIMM, Dr Monica Montopoli, states, "In order to validate the hypothesis that hormone regulation shows implicating in the clinical outcome of COVID-19 patients, we evaluated the prevalence of SARS-CoV-2 infection, hospitalization, and death in women with hormone-dependent tumors being treated with anti-estrogen therapy. Although a larger sample and further molecular studies to better understand the mechanism and protective effect observed in females being treated with SERMs is needed, the study may identify a possible way to prevent or mitigate the effects of the virus.”

[summary] => [format] => 2 [safe_value] =>

Published in the scientific journal ‘Annals of Oncology’, the paper entitled Clinical outcome of SARS-CoV-2 infection in breast and ovarian cancer patients underwent anti-estrogenic therapy was authored by researchers Monica Montopoli (VIMM-University of Padua) and Arianna Calcinotto (IOR of Bellinzona). The research demonstrates how SERM drugs (Selective Estrogen Receptor Modulators) could possibly counteract SARS-CoV-2 infection and subsequent virus development. Carried out in close collaboration between VIMM-University of Padua, the Veneto Cancer Registry and the IOR of Bellinzona, the study examined 51,060 women from the Veneto Region who have been tested for the SARS-CoV-2 infection.

Building on the work and research carried out at VIMM last year that showed patients with prostate cancer treated with androgen deprivation therapies (ADT) demonstrated a lower risk of infection and development of Covid-19 than patients with untreated prostate cancer. The study focused on the possible role of steroid hormones in the Covid-19 therapeutic strategy.

The study investigates how sex hormones influence those infected with Covid-19. Sex hormones play a role in regulating the immune system, which then effects proteins involved in SARS Cov-2 infection, such as ACE2 and TMPRSS differently. Using the sample of women tested, there was a reduced prevalence of infection in patients undergoing hormone-dependent tumors SERM therapy (Selective Estrogen Receptor Modulators). This suggests an off-target effect played by SERMs that potentially involves an alteration in the mechanism of between the virus and the host cell, identifying a possible clinical use in the treatment of COVID-19 patients.

The results, in line with the recent discovery developed by Exscalate4CoV, the public-private consortium supported by the European Commission’s Horizon 2020 call, provides for an efficacy of raloxifene as a potential drug against COVID-19 that will be further validated by a larger cohort of women infected with SARS-Cov-2 and corrected for several variables.

The Associated Investigator from VIMM, Dr Monica Montopoli, states, "In order to validate the hypothesis that hormone regulation shows implicating in the clinical outcome of COVID-19 patients, we evaluated the prevalence of SARS-CoV-2 infection, hospitalization, and death in women with hormone-dependent tumors being treated with anti-estrogen therapy. Although a larger sample and further molecular studies to better understand the mechanism and protective effect observed in females being treated with SERMs is needed, the study may identify a possible way to prevent or mitigate the effects of the virus.”

[safe_summary] => ) ) ) [field_date_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [value] => 2021-03-04T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_etichetta_box_lancio_news] => Array ( ) [field_img_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [fid] => 90881 [uid] => 2032 [filename] => n_ospedale_letto.jpg [uri] => public://n_ospedale_letto.jpg [filemime] => image/jpeg [filesize] => 51038 [status] => 1 [timestamp] => 1614859174 [type] => image [field_file_image_alt_text] => Array ( ) [field_file_image_title_text] => Array ( ) [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( [height] => 630 [width] => 1200 ) [height] => 630 [width] => 1200 [alt] => hospital [title] => ) ) ) [field_link_alla_news] => Array ( ) [field_link_esterno_news] => Array ( [und] => Array ( [0] => Array ( [value] => [format] => [safe_value] => ) ) ) [field_pagina_associata] => Array ( ) [field_link_etichetta] => Array ( ) [field_abstract_news] => Array ( [und] => Array ( [0] => Array ( [value] => The collaborative research conducted between VIMM, the University of Padua, the Veneto Cancer Registry, and the Institute of Oncology Research (IOR) of Bellinzona shows how anti-estrogen drugs (SERMs) administered to women for breast cancer treatment blocks Covid-19. [format] => [safe_value] => The collaborative research conducted between VIMM, the University of Padua, the Veneto Cancer Registry, and the Institute of Oncology Research (IOR) of Bellinzona shows how anti-estrogen drugs (SERMs) administered to women for breast cancer treatment blocks Covid-19. ) ) ) [field_allegato_news] => Array ( ) [field_categorie_news] => Array ( [und] => Array ( [0] => Array ( [tid] => 2296 ) ) ) [field_pub_date] => Array ( [und] => Array ( [0] => Array ( [value] => 2021-03-04T00:00:00 [value2] => 2021-12-04T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_layout_news] => Array ( [und] => Array ( [0] => Array ( [value] => single ) ) ) [field_testo_opzionale_news] => Array ( ) [field_url_en_page] => Array ( ) [field_url_en_page_label] => Array ( ) [path] => Array ( [pathauto] => 1 ) [name] => francesca.forzan [picture] => 0 [data] => b:0; [num_revisions] => 1 [current_revision_id] => 348014 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [value] => The collaborative research conducted between VIMM, the University of Padua, the Veneto Cancer Registry, and the Institute of Oncology Research (IOR) of Bellinzona shows how anti-estrogen drugs (SERMs) administered to women for breast cancer treatment blocks Covid-19. [format] => [safe_value] => The collaborative research conducted between VIMM, the University of Padua, the Veneto Cancer Registry, and the Institute of Oncology Research (IOR) of Bellinzona shows how anti-estrogen drugs (SERMs) administered to women for breast cancer treatment blocks Covid-19. ) ) [#formatter] => text_default [0] => Array ( [#markup] => The collaborative research conducted between VIMM, the University of Padua, the Veneto Cancer Registry, and the Institute of Oncology Research (IOR) of Bellinzona shows how anti-estrogen drugs (SERMs) administered to women for breast cancer treatment blocks Covid-19. ) ) [links] => Array ( [#theme] => links__node [#pre_render] => Array ( [0] => drupal_pre_render_links ) [#attributes] => Array ( [class] => Array ( [0] => links [1] => inline ) ) [node] => Array ( [#theme] => links__node__node [#links] => Array ( [node-readmore] => Array ( [title] => Read more about SERM drug therapy to counter SARS-CoV-2 infection and virus development [href] => node/75932 [html] => 1 [attributes] => Array ( [rel] => tag [title] => SERM drug therapy to counter SARS-CoV-2 infection and virus development ) ) ) [#attributes] => Array ( [class] => Array ( [0] => links [1] => inline ) ) ) ) [field_date_box_lancio_news] => Array ( [#theme] => field [#weight] => 1 [#title] => Data [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_date_box_lancio_news [#field_type] => date [#field_translatable] => 0 [#entity_type] => node [#bundle] => box_lancio_news [#object] => stdClass Object ( [vid] => 348014 [uid] => 2032 [title] => SERM drug therapy to counter SARS-CoV-2 infection and virus development [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 75932 [type] => box_lancio_news [language] => it [created] => 1614859174 [changed] => 1614859174 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1614859174 [revision_uid] => 2032 [body] => Array ( [und] => Array ( [0] => Array ( [value] =>

Published in the scientific journal ‘Annals of Oncology’, the paper entitled Clinical outcome of SARS-CoV-2 infection in breast and ovarian cancer patients underwent anti-estrogenic therapy was authored by researchers Monica Montopoli (VIMM-University of Padua) and Arianna Calcinotto (IOR of Bellinzona). The research demonstrates how SERM drugs (Selective Estrogen Receptor Modulators) could possibly counteract SARS-CoV-2 infection and subsequent virus development. Carried out in close collaboration between VIMM-University of Padua, the Veneto Cancer Registry and the IOR of Bellinzona, the study examined 51,060 women from the Veneto Region who have been tested for the SARS-CoV-2 infection.

Building on the work and research carried out at VIMM last year that showed patients with prostate cancer treated with androgen deprivation therapies (ADT) demonstrated a lower risk of infection and development of Covid-19 than patients with untreated prostate cancer. The study focused on the possible role of steroid hormones in the Covid-19 therapeutic strategy.

The study investigates how sex hormones influence those infected with Covid-19. Sex hormones play a role in regulating the immune system, which then effects proteins involved in SARS Cov-2 infection, such as ACE2 and TMPRSS differently. Using the sample of women tested, there was a reduced prevalence of infection in patients undergoing hormone-dependent tumors SERM therapy (Selective Estrogen Receptor Modulators). This suggests an off-target effect played by SERMs that potentially involves an alteration in the mechanism of between the virus and the host cell, identifying a possible clinical use in the treatment of COVID-19 patients.

The results, in line with the recent discovery developed by Exscalate4CoV, the public-private consortium supported by the European Commission’s Horizon 2020 call, provides for an efficacy of raloxifene as a potential drug against COVID-19 that will be further validated by a larger cohort of women infected with SARS-Cov-2 and corrected for several variables.

The Associated Investigator from VIMM, Dr Monica Montopoli, states, "In order to validate the hypothesis that hormone regulation shows implicating in the clinical outcome of COVID-19 patients, we evaluated the prevalence of SARS-CoV-2 infection, hospitalization, and death in women with hormone-dependent tumors being treated with anti-estrogen therapy. Although a larger sample and further molecular studies to better understand the mechanism and protective effect observed in females being treated with SERMs is needed, the study may identify a possible way to prevent or mitigate the effects of the virus.”

[summary] => [format] => 2 [safe_value] =>

Published in the scientific journal ‘Annals of Oncology’, the paper entitled Clinical outcome of SARS-CoV-2 infection in breast and ovarian cancer patients underwent anti-estrogenic therapy was authored by researchers Monica Montopoli (VIMM-University of Padua) and Arianna Calcinotto (IOR of Bellinzona). The research demonstrates how SERM drugs (Selective Estrogen Receptor Modulators) could possibly counteract SARS-CoV-2 infection and subsequent virus development. Carried out in close collaboration between VIMM-University of Padua, the Veneto Cancer Registry and the IOR of Bellinzona, the study examined 51,060 women from the Veneto Region who have been tested for the SARS-CoV-2 infection.

Building on the work and research carried out at VIMM last year that showed patients with prostate cancer treated with androgen deprivation therapies (ADT) demonstrated a lower risk of infection and development of Covid-19 than patients with untreated prostate cancer. The study focused on the possible role of steroid hormones in the Covid-19 therapeutic strategy.

The study investigates how sex hormones influence those infected with Covid-19. Sex hormones play a role in regulating the immune system, which then effects proteins involved in SARS Cov-2 infection, such as ACE2 and TMPRSS differently. Using the sample of women tested, there was a reduced prevalence of infection in patients undergoing hormone-dependent tumors SERM therapy (Selective Estrogen Receptor Modulators). This suggests an off-target effect played by SERMs that potentially involves an alteration in the mechanism of between the virus and the host cell, identifying a possible clinical use in the treatment of COVID-19 patients.

The results, in line with the recent discovery developed by Exscalate4CoV, the public-private consortium supported by the European Commission’s Horizon 2020 call, provides for an efficacy of raloxifene as a potential drug against COVID-19 that will be further validated by a larger cohort of women infected with SARS-Cov-2 and corrected for several variables.

The Associated Investigator from VIMM, Dr Monica Montopoli, states, "In order to validate the hypothesis that hormone regulation shows implicating in the clinical outcome of COVID-19 patients, we evaluated the prevalence of SARS-CoV-2 infection, hospitalization, and death in women with hormone-dependent tumors being treated with anti-estrogen therapy. Although a larger sample and further molecular studies to better understand the mechanism and protective effect observed in females being treated with SERMs is needed, the study may identify a possible way to prevent or mitigate the effects of the virus.”

[safe_summary] => ) ) ) [field_date_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [value] => 2021-03-04T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_etichetta_box_lancio_news] => Array ( ) [field_img_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [fid] => 90881 [uid] => 2032 [filename] => n_ospedale_letto.jpg [uri] => public://n_ospedale_letto.jpg [filemime] => image/jpeg [filesize] => 51038 [status] => 1 [timestamp] => 1614859174 [type] => image [field_file_image_alt_text] => Array ( ) [field_file_image_title_text] => Array ( ) [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( [height] => 630 [width] => 1200 ) [height] => 630 [width] => 1200 [alt] => hospital [title] => ) ) ) [field_link_alla_news] => Array ( ) [field_link_esterno_news] => Array ( [und] => Array ( [0] => Array ( [value] => [format] => [safe_value] => ) ) ) [field_pagina_associata] => Array ( ) [field_link_etichetta] => Array ( ) [field_abstract_news] => Array ( [und] => Array ( [0] => Array ( [value] => The collaborative research conducted between VIMM, the University of Padua, the Veneto Cancer Registry, and the Institute of Oncology Research (IOR) of Bellinzona shows how anti-estrogen drugs (SERMs) administered to women for breast cancer treatment blocks Covid-19. [format] => [safe_value] => The collaborative research conducted between VIMM, the University of Padua, the Veneto Cancer Registry, and the Institute of Oncology Research (IOR) of Bellinzona shows how anti-estrogen drugs (SERMs) administered to women for breast cancer treatment blocks Covid-19. ) ) ) [field_allegato_news] => Array ( ) [field_categorie_news] => Array ( [und] => Array ( [0] => Array ( [tid] => 2296 ) ) ) [field_pub_date] => Array ( [und] => Array ( [0] => Array ( [value] => 2021-03-04T00:00:00 [value2] => 2021-12-04T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_layout_news] => Array ( [und] => Array ( [0] => Array ( [value] => single ) ) ) [field_testo_opzionale_news] => Array ( ) [field_url_en_page] => Array ( ) [field_url_en_page_label] => Array ( ) [path] => Array ( [pathauto] => 1 ) [name] => francesca.forzan [picture] => 0 [data] => b:0; [num_revisions] => 1 [current_revision_id] => 348014 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [value] => 2021-03-04T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) [#formatter] => date_default [0] => Array ( [#markup] => Gio, 04/03/2021 ) ) )

2020RUA07 - Allegato 1 - Verbale 2 - Elenco candidati e convocazione

Array ( [field_titolo_frontend_all] => Array ( [#theme] => field [#weight] => -4 [#title] => Titolo frontend [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_titolo_frontend_all [#field_type] => text_long [#field_translatable] => 0 [#entity_type] => node [#bundle] => allegato [#object] => stdClass Object ( [vid] => 348007 [uid] => 8831 [title] => 2020RUA07 - Allegato 1 - Verbale 2 - Elenco candidati e convocazione [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 75931 [type] => allegato [language] => it [created] => 1614855971 [changed] => 1617700162 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1617700162 [revision_uid] => 102 [taxonomy_vocabulary_2] => Array ( ) [taxonomy_vocabulary_8] => Array ( ) [body] => Array ( ) [field_titolo_frontend_all] => Array ( [und] => Array ( [0] => Array ( [value] => Verbale 2 - Elenco candidati e convocazione [format] => [safe_value] => Verbale 2 - Elenco candidati e convocazione ) ) ) [field_allegato_file] => Array ( [und] => Array ( [0] => Array ( [fid] => 90879 [uid] => 32 [filename] => Verbale 2 AGR19.pdf [uri] => public://2021/Verbale 2 AGR19.pdf [filemime] => application/pdf [filesize] => 1051378 [status] => 1 [timestamp] => 1614855967 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2408 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [name] => carriere.docenti [picture] => 0 [data] => [num_revisions] => 1 [current_revision_id] => 348007 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [value] => Verbale 2 - Elenco candidati e convocazione [format] => [safe_value] => Verbale 2 - Elenco candidati e convocazione ) ) [#formatter] => text_default [0] => Array ( [#markup] => Verbale 2 - Elenco candidati e convocazione ) ) [field_allegato_file] => Array ( [#theme] => field [#weight] => -3 [#title] => File [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_allegato_file [#field_type] => file [#field_translatable] => 0 [#entity_type] => node [#bundle] => allegato [#object] => stdClass Object ( [vid] => 348007 [uid] => 8831 [title] => 2020RUA07 - Allegato 1 - Verbale 2 - Elenco candidati e convocazione [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 75931 [type] => allegato [language] => it [created] => 1614855971 [changed] => 1617700162 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1617700162 [revision_uid] => 102 [taxonomy_vocabulary_2] => Array ( ) [taxonomy_vocabulary_8] => Array ( ) [body] => Array ( ) [field_titolo_frontend_all] => Array ( [und] => Array ( [0] => Array ( [value] => Verbale 2 - Elenco candidati e convocazione [format] => [safe_value] => Verbale 2 - Elenco candidati e convocazione ) ) ) [field_allegato_file] => Array ( [und] => Array ( [0] => Array ( [fid] => 90879 [uid] => 32 [filename] => Verbale 2 AGR19.pdf [uri] => public://2021/Verbale 2 AGR19.pdf [filemime] => application/pdf [filesize] => 1051378 [status] => 1 [timestamp] => 1614855967 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2408 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [name] => carriere.docenti [picture] => 0 [data] => [num_revisions] => 1 [current_revision_id] => 348007 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [fid] => 90879 [uid] => 32 [filename] => Verbale 2 AGR19.pdf [uri] => public://2021/Verbale 2 AGR19.pdf [filemime] => application/pdf [filesize] => 1051378 [status] => 1 [timestamp] => 1614855967 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2408 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) [#formatter] => file_default [0] => Array ( [#theme] => file_link [#file] => stdClass Object ( [fid] => 90879 [uid] => 32 [filename] => Verbale 2 AGR19.pdf [uri] => public://2021/Verbale 2 AGR19.pdf [filemime] => application/pdf [filesize] => 1051378 [status] => 1 [timestamp] => 1614855967 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2408 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [links] => Array ( [#theme] => links__node [#pre_render] => Array ( [0] => drupal_pre_render_links ) [#attributes] => Array ( [class] => Array ( [0] => links [1] => inline ) ) [node] => Array ( [#theme] => links__node__node [#links] => Array ( [node-readmore] => Array ( [title] => Read more about 2020RUA07 - Allegato 1 - Verbale 2 - Elenco candidati e convocazione [href] => node/75931 [html] => 1 [attributes] => Array ( [rel] => tag [title] => 2020RUA07 - Allegato 1 - Verbale 2 - Elenco candidati e convocazione ) ) ) [#attributes] => Array ( [class] => Array ( [0] => links [1] => inline ) ) ) ) )

2020RUA07 - Allegato 1 - Verbale 1 - Criteri

Array ( [field_titolo_frontend_all] => Array ( [#theme] => field [#weight] => -4 [#title] => Titolo frontend [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_titolo_frontend_all [#field_type] => text_long [#field_translatable] => 0 [#entity_type] => node [#bundle] => allegato [#object] => stdClass Object ( [vid] => 348006 [uid] => 8831 [title] => 2020RUA07 - Allegato 1 - Verbale 1 - Criteri [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 75930 [type] => allegato [language] => it [created] => 1614855935 [changed] => 1617700162 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1617700162 [revision_uid] => 102 [taxonomy_vocabulary_2] => Array ( ) [taxonomy_vocabulary_8] => Array ( ) [body] => Array ( ) [field_titolo_frontend_all] => Array ( [und] => Array ( [0] => Array ( [value] => Verbale 1 - Criteri [format] => [safe_value] => Verbale 1 - Criteri ) ) ) [field_allegato_file] => Array ( [und] => Array ( [0] => Array ( [fid] => 90878 [uid] => 32 [filename] => Verbale n 1 AGR19.pdf [uri] => public://2021/Verbale n 1 AGR19.pdf [filemime] => application/pdf [filesize] => 4161106 [status] => 1 [timestamp] => 1614855931 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2408 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [name] => carriere.docenti [picture] => 0 [data] => [num_revisions] => 1 [current_revision_id] => 348006 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [value] => Verbale 1 - Criteri [format] => [safe_value] => Verbale 1 - Criteri ) ) [#formatter] => text_default [0] => Array ( [#markup] => Verbale 1 - Criteri ) ) [field_allegato_file] => Array ( [#theme] => field [#weight] => -3 [#title] => File [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_allegato_file [#field_type] => file [#field_translatable] => 0 [#entity_type] => node [#bundle] => allegato [#object] => stdClass Object ( [vid] => 348006 [uid] => 8831 [title] => 2020RUA07 - Allegato 1 - Verbale 1 - Criteri [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 75930 [type] => allegato [language] => it [created] => 1614855935 [changed] => 1617700162 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1617700162 [revision_uid] => 102 [taxonomy_vocabulary_2] => Array ( ) [taxonomy_vocabulary_8] => Array ( ) [body] => Array ( ) [field_titolo_frontend_all] => Array ( [und] => Array ( [0] => Array ( [value] => Verbale 1 - Criteri [format] => [safe_value] => Verbale 1 - Criteri ) ) ) [field_allegato_file] => Array ( [und] => Array ( [0] => Array ( [fid] => 90878 [uid] => 32 [filename] => Verbale n 1 AGR19.pdf [uri] => public://2021/Verbale n 1 AGR19.pdf [filemime] => application/pdf [filesize] => 4161106 [status] => 1 [timestamp] => 1614855931 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2408 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [name] => carriere.docenti [picture] => 0 [data] => [num_revisions] => 1 [current_revision_id] => 348006 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [fid] => 90878 [uid] => 32 [filename] => Verbale n 1 AGR19.pdf [uri] => public://2021/Verbale n 1 AGR19.pdf [filemime] => application/pdf [filesize] => 4161106 [status] => 1 [timestamp] => 1614855931 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2408 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) [#formatter] => file_default [0] => Array ( [#theme] => file_link [#file] => stdClass Object ( [fid] => 90878 [uid] => 32 [filename] => Verbale n 1 AGR19.pdf [uri] => public://2021/Verbale n 1 AGR19.pdf [filemime] => application/pdf [filesize] => 4161106 [status] => 1 [timestamp] => 1614855931 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2408 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [links] => Array ( [#theme] => links__node [#pre_render] => Array ( [0] => drupal_pre_render_links ) [#attributes] => Array ( [class] => Array ( [0] => links [1] => inline ) ) [node] => Array ( [#theme] => links__node__node [#links] => Array ( [node-readmore] => Array ( [title] => Read more about 2020RUA07 - Allegato 1 - Verbale 1 - Criteri [href] => node/75930 [html] => 1 [attributes] => Array ( [rel] => tag [title] => 2020RUA07 - Allegato 1 - Verbale 1 - Criteri ) ) ) [#attributes] => Array ( [class] => Array ( [0] => links [1] => inline ) ) ) ) )

2020RUA03 - Allegato 17 - Verbale 1 - criteri

Array ( [field_titolo_frontend_all] => Array ( [#theme] => field [#weight] => -4 [#title] => Titolo frontend [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_titolo_frontend_all [#field_type] => text_long [#field_translatable] => 0 [#entity_type] => node [#bundle] => allegato [#object] => stdClass Object ( [vid] => 348005 [uid] => 8831 [title] => 2020RUA03 - Allegato 17 - Verbale 1 - criteri [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 75929 [type] => allegato [language] => it [created] => 1614853754 [changed] => 1617700162 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1617700162 [revision_uid] => 102 [taxonomy_vocabulary_2] => Array ( ) [taxonomy_vocabulary_8] => Array ( ) [body] => Array ( ) [field_titolo_frontend_all] => Array ( [und] => Array ( [0] => Array ( [value] => Verbale 1 - criteri [format] => [safe_value] => Verbale 1 - criteri ) ) ) [field_allegato_file] => Array ( [und] => Array ( [0] => Array ( [fid] => 90876 [uid] => 32 [filename] => verbale 1 A.pdf [uri] => public://2021/verbale 1 A_2.pdf [filemime] => application/pdf [filesize] => 1290347 [status] => 1 [timestamp] => 1614853745 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2408 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [name] => carriere.docenti [picture] => 0 [data] => [num_revisions] => 1 [current_revision_id] => 348005 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [value] => Verbale 1 - criteri [format] => [safe_value] => Verbale 1 - criteri ) ) [#formatter] => text_default [0] => Array ( [#markup] => Verbale 1 - criteri ) ) [field_allegato_file] => Array ( [#theme] => field [#weight] => -3 [#title] => File [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_allegato_file [#field_type] => file [#field_translatable] => 0 [#entity_type] => node [#bundle] => allegato [#object] => stdClass Object ( [vid] => 348005 [uid] => 8831 [title] => 2020RUA03 - Allegato 17 - Verbale 1 - criteri [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 75929 [type] => allegato [language] => it [created] => 1614853754 [changed] => 1617700162 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1617700162 [revision_uid] => 102 [taxonomy_vocabulary_2] => Array ( ) [taxonomy_vocabulary_8] => Array ( ) [body] => Array ( ) [field_titolo_frontend_all] => Array ( [und] => Array ( [0] => Array ( [value] => Verbale 1 - criteri [format] => [safe_value] => Verbale 1 - criteri ) ) ) [field_allegato_file] => Array ( [und] => Array ( [0] => Array ( [fid] => 90876 [uid] => 32 [filename] => verbale 1 A.pdf [uri] => public://2021/verbale 1 A_2.pdf [filemime] => application/pdf [filesize] => 1290347 [status] => 1 [timestamp] => 1614853745 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2408 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [name] => carriere.docenti [picture] => 0 [data] => [num_revisions] => 1 [current_revision_id] => 348005 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [fid] => 90876 [uid] => 32 [filename] => verbale 1 A.pdf [uri] => public://2021/verbale 1 A_2.pdf [filemime] => application/pdf [filesize] => 1290347 [status] => 1 [timestamp] => 1614853745 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2408 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) [#formatter] => file_default [0] => Array ( [#theme] => file_link [#file] => stdClass Object ( [fid] => 90876 [uid] => 32 [filename] => verbale 1 A.pdf [uri] => public://2021/verbale 1 A_2.pdf [filemime] => application/pdf [filesize] => 1290347 [status] => 1 [timestamp] => 1614853745 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2408 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [links] => Array ( [#theme] => links__node [#pre_render] => Array ( [0] => drupal_pre_render_links ) [#attributes] => Array ( [class] => Array ( [0] => links [1] => inline ) ) [node] => Array ( [#theme] => links__node__node [#links] => Array ( [node-readmore] => Array ( [title] => Read more about 2020RUA03 - Allegato 17 - Verbale 1 - criteri [href] => node/75929 [html] => 1 [attributes] => Array ( [rel] => tag [title] => 2020RUA03 - Allegato 17 - Verbale 1 - criteri ) ) ) [#attributes] => Array ( [class] => Array ( [0] => links [1] => inline ) ) ) ) )

2020RUA04 - Allegato 11 - Avviso link per colloquio telematico

Array ( [field_titolo_frontend_all] => Array ( [#theme] => field [#weight] => -4 [#title] => Titolo frontend [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_titolo_frontend_all [#field_type] => text_long [#field_translatable] => 0 [#entity_type] => node [#bundle] => allegato [#object] => stdClass Object ( [vid] => 348002 [uid] => 8831 [title] => 2020RUA04 - Allegato 11 - Avviso link per colloquio telematico [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 75927 [type] => allegato [language] => it [created] => 1614853270 [changed] => 1617700162 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1617700162 [revision_uid] => 102 [taxonomy_vocabulary_2] => Array ( ) [taxonomy_vocabulary_8] => Array ( ) [body] => Array ( ) [field_titolo_frontend_all] => Array ( [und] => Array ( [0] => Array ( [value] => Avviso link per colloquio telematico [format] => [safe_value] => Avviso link per colloquio telematico ) ) ) [field_allegato_file] => Array ( [und] => Array ( [0] => Array ( [fid] => 90874 [uid] => 32 [filename] => Avviso link colloquio telematico.docx.pdf [uri] => public://2021/Avviso link colloquio telematico.docx.pdf [filemime] => application/pdf [filesize] => 137918 [status] => 1 [timestamp] => 1614853266 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2408 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [name] => carriere.docenti [picture] => 0 [data] => [num_revisions] => 1 [current_revision_id] => 348002 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [value] => Avviso link per colloquio telematico [format] => [safe_value] => Avviso link per colloquio telematico ) ) [#formatter] => text_default [0] => Array ( [#markup] => Avviso link per colloquio telematico ) ) [field_allegato_file] => Array ( [#theme] => field [#weight] => -3 [#title] => File [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_allegato_file [#field_type] => file [#field_translatable] => 0 [#entity_type] => node [#bundle] => allegato [#object] => stdClass Object ( [vid] => 348002 [uid] => 8831 [title] => 2020RUA04 - Allegato 11 - Avviso link per colloquio telematico [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 75927 [type] => allegato [language] => it [created] => 1614853270 [changed] => 1617700162 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1617700162 [revision_uid] => 102 [taxonomy_vocabulary_2] => Array ( ) [taxonomy_vocabulary_8] => Array ( ) [body] => Array ( ) [field_titolo_frontend_all] => Array ( [und] => Array ( [0] => Array ( [value] => Avviso link per colloquio telematico [format] => [safe_value] => Avviso link per colloquio telematico ) ) ) [field_allegato_file] => Array ( [und] => Array ( [0] => Array ( [fid] => 90874 [uid] => 32 [filename] => Avviso link colloquio telematico.docx.pdf [uri] => public://2021/Avviso link colloquio telematico.docx.pdf [filemime] => application/pdf [filesize] => 137918 [status] => 1 [timestamp] => 1614853266 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2408 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [name] => carriere.docenti [picture] => 0 [data] => [num_revisions] => 1 [current_revision_id] => 348002 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [fid] => 90874 [uid] => 32 [filename] => Avviso link colloquio telematico.docx.pdf [uri] => public://2021/Avviso link colloquio telematico.docx.pdf [filemime] => application/pdf [filesize] => 137918 [status] => 1 [timestamp] => 1614853266 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2408 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) [#formatter] => file_default [0] => Array ( [#theme] => file_link [#file] => stdClass Object ( [fid] => 90874 [uid] => 32 [filename] => Avviso link colloquio telematico.docx.pdf [uri] => public://2021/Avviso link colloquio telematico.docx.pdf [filemime] => application/pdf [filesize] => 137918 [status] => 1 [timestamp] => 1614853266 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2408 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [links] => Array ( [#theme] => links__node [#pre_render] => Array ( [0] => drupal_pre_render_links ) [#attributes] => Array ( [class] => Array ( [0] => links [1] => inline ) ) [node] => Array ( [#theme] => links__node__node [#links] => Array ( [node-readmore] => Array ( [title] => Read more about 2020RUA04 - Allegato 11 - Avviso link per colloquio telematico [href] => node/75927 [html] => 1 [attributes] => Array ( [rel] => tag [title] => 2020RUA04 - Allegato 11 - Avviso link per colloquio telematico ) ) ) [#attributes] => Array ( [class] => Array ( [0] => links [1] => inline ) ) ) ) )

2020RUA05 - Allegato 7 - DR approvazione atti

Array ( [field_titolo_frontend_all] => Array ( [#theme] => field [#weight] => -4 [#title] => Titolo frontend [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_titolo_frontend_all [#field_type] => text_long [#field_translatable] => 0 [#entity_type] => node [#bundle] => allegato [#object] => stdClass Object ( [vid] => 348000 [uid] => 8831 [title] => 2020RUA05 - Allegato 7 - DR approvazione atti [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 75926 [type] => allegato [language] => it [created] => 1614852663 [changed] => 1617700162 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1617700162 [revision_uid] => 102 [taxonomy_vocabulary_2] => Array ( ) [taxonomy_vocabulary_8] => Array ( ) [body] => Array ( ) [field_titolo_frontend_all] => Array ( [und] => Array ( [0] => Array ( [value] => DR approvazione atti [format] => [safe_value] => DR approvazione atti ) ) ) [field_allegato_file] => Array ( [und] => Array ( [0] => Array ( [fid] => 90872 [uid] => 32 [filename] => DR approvazione atti SPS 01 con prot.docx.pdf [uri] => public://2021/DR approvazione atti SPS 01 con prot.docx.pdf [filemime] => application/pdf [filesize] => 145956 [status] => 1 [timestamp] => 1614852659 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2408 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [name] => carriere.docenti [picture] => 0 [data] => [num_revisions] => 1 [current_revision_id] => 348000 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [value] => DR approvazione atti [format] => [safe_value] => DR approvazione atti ) ) [#formatter] => text_default [0] => Array ( [#markup] => DR approvazione atti ) ) [field_allegato_file] => Array ( [#theme] => field [#weight] => -3 [#title] => File [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_allegato_file [#field_type] => file [#field_translatable] => 0 [#entity_type] => node [#bundle] => allegato [#object] => stdClass Object ( [vid] => 348000 [uid] => 8831 [title] => 2020RUA05 - Allegato 7 - DR approvazione atti [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 75926 [type] => allegato [language] => it [created] => 1614852663 [changed] => 1617700162 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1617700162 [revision_uid] => 102 [taxonomy_vocabulary_2] => Array ( ) [taxonomy_vocabulary_8] => Array ( ) [body] => Array ( ) [field_titolo_frontend_all] => Array ( [und] => Array ( [0] => Array ( [value] => DR approvazione atti [format] => [safe_value] => DR approvazione atti ) ) ) [field_allegato_file] => Array ( [und] => Array ( [0] => Array ( [fid] => 90872 [uid] => 32 [filename] => DR approvazione atti SPS 01 con prot.docx.pdf [uri] => public://2021/DR approvazione atti SPS 01 con prot.docx.pdf [filemime] => application/pdf [filesize] => 145956 [status] => 1 [timestamp] => 1614852659 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2408 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [name] => carriere.docenti [picture] => 0 [data] => [num_revisions] => 1 [current_revision_id] => 348000 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [fid] => 90872 [uid] => 32 [filename] => DR approvazione atti SPS 01 con prot.docx.pdf [uri] => public://2021/DR approvazione atti SPS 01 con prot.docx.pdf [filemime] => application/pdf [filesize] => 145956 [status] => 1 [timestamp] => 1614852659 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2408 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) [#formatter] => file_default [0] => Array ( [#theme] => file_link [#file] => stdClass Object ( [fid] => 90872 [uid] => 32 [filename] => DR approvazione atti SPS 01 con prot.docx.pdf [uri] => public://2021/DR approvazione atti SPS 01 con prot.docx.pdf [filemime] => application/pdf [filesize] => 145956 [status] => 1 [timestamp] => 1614852659 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2408 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [links] => Array ( [#theme] => links__node [#pre_render] => Array ( [0] => drupal_pre_render_links ) [#attributes] => Array ( [class] => Array ( [0] => links [1] => inline ) ) [node] => Array ( [#theme] => links__node__node [#links] => Array ( [node-readmore] => Array ( [title] => Read more about 2020RUA05 - Allegato 7 - DR approvazione atti [href] => node/75926 [html] => 1 [attributes] => Array ( [rel] => tag [title] => 2020RUA05 - Allegato 7 - DR approvazione atti ) ) ) [#attributes] => Array ( [class] => Array ( [0] => links [1] => inline ) ) ) ) )

2020RUA05 - Allegato 7 - Giudizi, punteggi, vincitore

Array ( [field_titolo_frontend_all] => Array ( [#theme] => field [#weight] => -4 [#title] => Titolo frontend [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_titolo_frontend_all [#field_type] => text_long [#field_translatable] => 0 [#entity_type] => node [#bundle] => allegato [#object] => stdClass Object ( [vid] => 347999 [uid] => 8831 [title] => 2020RUA05 - Allegato 7 - Giudizi, punteggi, vincitore [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 75925 [type] => allegato [language] => it [created] => 1614852619 [changed] => 1617700162 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1617700162 [revision_uid] => 102 [taxonomy_vocabulary_2] => Array ( ) [taxonomy_vocabulary_8] => Array ( ) [body] => Array ( ) [field_titolo_frontend_all] => Array ( [und] => Array ( [0] => Array ( [value] => Giudizi, punteggi, vincitore [format] => [safe_value] => Giudizi, punteggi, vincitore ) ) ) [field_allegato_file] => Array ( [und] => Array ( [0] => Array ( [fid] => 90871 [uid] => 32 [filename] => web QUARTO VERBALE_CONCORSO RTDA_SPS-01 con prot_compressed.pdf [uri] => public://2021/web QUARTO VERBALE_CONCORSO RTDA_SPS-01 con prot_compressed.pdf [filemime] => application/pdf [filesize] => 1063117 [status] => 1 [timestamp] => 1614852615 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2408 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [name] => carriere.docenti [picture] => 0 [data] => [num_revisions] => 1 [current_revision_id] => 347999 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [value] => Giudizi, punteggi, vincitore [format] => [safe_value] => Giudizi, punteggi, vincitore ) ) [#formatter] => text_default [0] => Array ( [#markup] => Giudizi, punteggi, vincitore ) ) [field_allegato_file] => Array ( [#theme] => field [#weight] => -3 [#title] => File [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_allegato_file [#field_type] => file [#field_translatable] => 0 [#entity_type] => node [#bundle] => allegato [#object] => stdClass Object ( [vid] => 347999 [uid] => 8831 [title] => 2020RUA05 - Allegato 7 - Giudizi, punteggi, vincitore [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 75925 [type] => allegato [language] => it [created] => 1614852619 [changed] => 1617700162 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1617700162 [revision_uid] => 102 [taxonomy_vocabulary_2] => Array ( ) [taxonomy_vocabulary_8] => Array ( ) [body] => Array ( ) [field_titolo_frontend_all] => Array ( [und] => Array ( [0] => Array ( [value] => Giudizi, punteggi, vincitore [format] => [safe_value] => Giudizi, punteggi, vincitore ) ) ) [field_allegato_file] => Array ( [und] => Array ( [0] => Array ( [fid] => 90871 [uid] => 32 [filename] => web QUARTO VERBALE_CONCORSO RTDA_SPS-01 con prot_compressed.pdf [uri] => public://2021/web QUARTO VERBALE_CONCORSO RTDA_SPS-01 con prot_compressed.pdf [filemime] => application/pdf [filesize] => 1063117 [status] => 1 [timestamp] => 1614852615 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2408 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [name] => carriere.docenti [picture] => 0 [data] => [num_revisions] => 1 [current_revision_id] => 347999 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [fid] => 90871 [uid] => 32 [filename] => web QUARTO VERBALE_CONCORSO RTDA_SPS-01 con prot_compressed.pdf [uri] => public://2021/web QUARTO VERBALE_CONCORSO RTDA_SPS-01 con prot_compressed.pdf [filemime] => application/pdf [filesize] => 1063117 [status] => 1 [timestamp] => 1614852615 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2408 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) [#formatter] => file_default [0] => Array ( [#theme] => file_link [#file] => stdClass Object ( [fid] => 90871 [uid] => 32 [filename] => web QUARTO VERBALE_CONCORSO RTDA_SPS-01 con prot_compressed.pdf [uri] => public://2021/web QUARTO VERBALE_CONCORSO RTDA_SPS-01 con prot_compressed.pdf [filemime] => application/pdf [filesize] => 1063117 [status] => 1 [timestamp] => 1614852615 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2408 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [links] => Array ( [#theme] => links__node [#pre_render] => Array ( [0] => drupal_pre_render_links ) [#attributes] => Array ( [class] => Array ( [0] => links [1] => inline ) ) [node] => Array ( [#theme] => links__node__node [#links] => Array ( [node-readmore] => Array ( [title] => Read more about 2020RUA05 - Allegato 7 - Giudizi, punteggi, vincitore [href] => node/75925 [html] => 1 [attributes] => Array ( [rel] => tag [title] => 2020RUA05 - Allegato 7 - Giudizi, punteggi, vincitore ) ) ) [#attributes] => Array ( [class] => Array ( [0] => links [1] => inline ) ) ) ) )

2020RUA05 - Allegato 2 - DR approvazione atti

Array ( [field_titolo_frontend_all] => Array ( [#theme] => field [#weight] => -4 [#title] => Titolo frontend [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_titolo_frontend_all [#field_type] => text_long [#field_translatable] => 0 [#entity_type] => node [#bundle] => allegato [#object] => stdClass Object ( [vid] => 347988 [uid] => 8831 [title] => 2020RUA05 - Allegato 2 - DR approvazione atti [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 75924 [type] => allegato [language] => it [created] => 1614850542 [changed] => 1617700177 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1617700177 [revision_uid] => 102 [taxonomy_vocabulary_2] => Array ( ) [taxonomy_vocabulary_8] => Array ( ) [body] => Array ( ) [field_titolo_frontend_all] => Array ( [und] => Array ( [0] => Array ( [value] => DR approvazione atti [format] => [safe_value] => DR approvazione atti ) ) ) [field_allegato_file] => Array ( [und] => Array ( [0] => Array ( [fid] => 90863 [uid] => 32 [filename] => DR approvazione atti ING-INF05.docx.pdf [uri] => public://2021/DR approvazione atti ING-INF05.docx.pdf [filemime] => application/pdf [filesize] => 146248 [status] => 1 [timestamp] => 1614850537 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2408 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [name] => carriere.docenti [picture] => 0 [data] => [num_revisions] => 1 [current_revision_id] => 347988 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [value] => DR approvazione atti [format] => [safe_value] => DR approvazione atti ) ) [#formatter] => text_default [0] => Array ( [#markup] => DR approvazione atti ) ) [field_allegato_file] => Array ( [#theme] => field [#weight] => -3 [#title] => File [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_allegato_file [#field_type] => file [#field_translatable] => 0 [#entity_type] => node [#bundle] => allegato [#object] => stdClass Object ( [vid] => 347988 [uid] => 8831 [title] => 2020RUA05 - Allegato 2 - DR approvazione atti [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 75924 [type] => allegato [language] => it [created] => 1614850542 [changed] => 1617700177 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1617700177 [revision_uid] => 102 [taxonomy_vocabulary_2] => Array ( ) [taxonomy_vocabulary_8] => Array ( ) [body] => Array ( ) [field_titolo_frontend_all] => Array ( [und] => Array ( [0] => Array ( [value] => DR approvazione atti [format] => [safe_value] => DR approvazione atti ) ) ) [field_allegato_file] => Array ( [und] => Array ( [0] => Array ( [fid] => 90863 [uid] => 32 [filename] => DR approvazione atti ING-INF05.docx.pdf [uri] => public://2021/DR approvazione atti ING-INF05.docx.pdf [filemime] => application/pdf [filesize] => 146248 [status] => 1 [timestamp] => 1614850537 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2408 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [name] => carriere.docenti [picture] => 0 [data] => [num_revisions] => 1 [current_revision_id] => 347988 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [fid] => 90863 [uid] => 32 [filename] => DR approvazione atti ING-INF05.docx.pdf [uri] => public://2021/DR approvazione atti ING-INF05.docx.pdf [filemime] => application/pdf [filesize] => 146248 [status] => 1 [timestamp] => 1614850537 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2408 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) [#formatter] => file_default [0] => Array ( [#theme] => file_link [#file] => stdClass Object ( [fid] => 90863 [uid] => 32 [filename] => DR approvazione atti ING-INF05.docx.pdf [uri] => public://2021/DR approvazione atti ING-INF05.docx.pdf [filemime] => application/pdf [filesize] => 146248 [status] => 1 [timestamp] => 1614850537 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2408 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [links] => Array ( [#theme] => links__node [#pre_render] => Array ( [0] => drupal_pre_render_links ) [#attributes] => Array ( [class] => Array ( [0] => links [1] => inline ) ) [node] => Array ( [#theme] => links__node__node [#links] => Array ( [node-readmore] => Array ( [title] => Read more about 2020RUA05 - Allegato 2 - DR approvazione atti [href] => node/75924 [html] => 1 [attributes] => Array ( [rel] => tag [title] => 2020RUA05 - Allegato 2 - DR approvazione atti ) ) ) [#attributes] => Array ( [class] => Array ( [0] => links [1] => inline ) ) ) ) )

Pagine